Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS20050287620 A1
Type de publicationDemande
Numéro de demandeUS 11/109,379
Date de publication29 déc. 2005
Date de dépôt19 avr. 2005
Date de priorité4 mars 1991
Autre référence de publicationDE69533260D1, DE69533260T2, EP0778897A1, EP0778897A4, EP0778897B1, US5593852, US5965380, US6083710, US6121009, US6162611, US6284478, US6329161, US6514718, US6881551, US7462264, US8588881, US8741590, US20020042090, US20030134347, US20060003398, US20070151869, US20070215491, US20070218097, US20100030044, US20100030046, US20100030047, US20100030048, US20100030049, US20100030050, US20100030051, US20100051479, US20100059370, US20100059371, US20100059372, US20100059373, US20100072063, US20100072064, US20100121165, US20100121166, WO1996006947A1
Numéro de publication109379, 11109379, US 2005/0287620 A1, US 2005/287620 A1, US 20050287620 A1, US 20050287620A1, US 2005287620 A1, US 2005287620A1, US-A1-20050287620, US-A1-2005287620, US2005/0287620A1, US2005/287620A1, US20050287620 A1, US20050287620A1, US2005287620 A1, US2005287620A1
InventeursAdam Heller, Michael Pishko
Cessionnaire d'origineTherasense, Inc.
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Method of determining analyte level using subcutaneous electrode
US 20050287620 A1
Résumé
A small diameter flexible electrode designed for subcutaneous in vivo amperometric monitoring of glucose is described. The electrode is designed to allow “one-point” in vivo calibration, i.e., to have zero output current at zero glucose concentration, even in the presence of other electroreactive species of serum or blood. The electrode is preferably three or four-layered, with the layers serially deposited within a recess upon the tip of a polyamide insulated gold wire. A first glucose concentration-to-current transducing layer is overcoated with an electrically insulating and glucose flux limiting layer (second layer) on which, optionally, an immobilized interference-eliminating horseradish peroxidase based film is deposited (third layer). An outer (fourth) layer is biocompatible.
Images(10)
Previous page
Next page
Revendications(25)
1. (canceled)
2. A method comprising:
(a) subcutaneously positing at least a portion of a first sensor in a patient;
(b) obtaining a first sensor reading from the first sensor related to an analyte level;
(c) obtaining a second sensor reading from a second sensor, the second sensor reading related to the analyte level;
(d) calibrating the first sensor using the second sensor reading.
3. The method of claim 2, wherein the step of obtaining a second sensor reading from a second sensor comprises:
(a) withdrawing a sample of blood from the patient; and
(b) obtaining the analyte level in the sample of blood with the second sensor.
4. The method of claim 3, wherein the step of withdrawing a sample of blood comprises withdrawing only a single sample of blood.
5. The method of claim 2, wherein the analyte is glucose.
6. The method of claim 2, wherein the step of obtaining a second sensor reading from a second sensor comprises:
(a) obtaining the second sensor reading from the second sensor after at least one hour of operation of the first sensor.
7. The method of claim 6, further comprising:
(a) obtaining a third sensor reading from a third sensor, the third sensor reading related to the analyte level; and
(b) calibrating the first sensor using the third sensor reading.
8. The method of claim 7, wherein the step of obtaining a third sensor reading from a third sensor comprises:
(a) withdrawing a sample of blood from the patient; and
(b) obtaining the analyte level in the sample of blood with the third sensor.
9. The method of claim 8, wherein the step of obtaining a third sensor reading from the third sensor comprises:
(a) obtaining the third sensor reading from the third sensor after 72 hours of operation of the first sensor.
10. The method of claim 2, wherein the step of subcutaneously positioning at least a portion of the first sensor in a patient comprises:
(a) subcutaneously positioning at least a portion of the first sensor in an abdomen, inner thigh, or arm of the patient.
11. The method of claim 2, wherein the second sensor is a subcutaneously implanted sensor.
12. A method comprising:
(a) subcutaneously positioning at least a portion of a first sensor in a patient;
(b) obtaining a first sensor reading from the first sensor related to an analyte level;
(c) obtaining a second sensor reading from a second sensor, the second sensor reading related to the analyte level;
(d) confirming the results of the first sensor reading with the second sensor reading.
13. The method of claim 12, wherein the step of obtaining a second sensor reading from a second sensor comprises:
(a) withdrawing a sample of blood from the patient; and
(b) obtaining the analyte level in the sample of blood with the second sensor.
14. The method of claim 13, wherein the step of withdrawing a sample of blood comprises withdrawing only a single sample of blood.
15. The method of claim 12, wherein the analyte is glucose.
16. The method of claim 12, wherein the step of obtaining a second sensor reading from a second sensor comprises:
(a) obtaining the second sensor reading from the second sensor after at least one hour of operation of the first sensor.
17. The method of claim 12, further comprising:
(a) obtaining a third sensor reading from a third sensor, the third sensor reading related to the analyte level; and
(b) confirming the results of the first sensor using the third sensor reading.
18. The method of claim 17, wherein the step of obtaining a third sensor reading from a third sensor comprises:
(a) withdrawing a sample of blood from the patient;
(b) obtaining the analyte level in the sample of blood with the third sensor.
19. The method of claim 17, wherein the step of obtaining a third sensor reading from the third sensor comprises:
(a) obtaining the third sensor reading from the third sensor after 72 hours of operation of the first sensor.
20. The method of claim 12, wherein the step of subcutaneously positioning at least a portion of the first sensor in a patient comprises:
(a) subcutaneously positioning at least a portion of the first sensor in an abdomen, inner thigh, or arm of the patient.
21. A method comprising:
(a) subcutaneously positioning at least a portion of a first sensor in a patient; and
(b) calibrating the first sensor after at least 1 hour of subcutaneously positioning the first sensor.
22. The method of claim 21, wherein the step of calibrating comprises:
(a) using a second sensor.
23. The method of claim 22, wherein the step of calibrating further comprises
(a) using a third sensor.
24. The method of claim 21, wherein the step of calibrating the first sensor after at least 1 hour comprises:
(a) calibrating the fist sensor periodically after at least 1 hour.
25. The method of claim 21, wherein the step of subcutaneously positioning at least a portion of the first sensor in a patient comprises:
(a) subcutaneously positioning at least a portion of the first sensor in an abdomen, inner thigh, or arm of the patient.
Description
  • [0001]
    This application is a Continuation of application Ser. No. 10/353,341, filed Jan. 28, 2003, now U.S. Pat. No. 6,881,551, which is a Continuation application of Ser. No. 09/997,808, filed Nov. 29, 2001, now U.S. Pat. No. 6,514,718, which is a Continuation application of Ser. No. 09/668,221, filed Sep. 22, 2000, now U.S. Pat. No. 6,239,161, which is a Continuation of application Ser. No. 09/477,053, filed Jan. 3, 2000, now U.S. Pat. No. 6,162,611, which is a Continuation of application Ser. No. 09/356,102, filed Jul. 16, 1999, now U.S. Pat. No. 6,121,009, which is a Continuation of application Ser. No. 08/767,110, filed Dec. 4, 1996, now U.S. Pat. No. 6,284,478, which is a continuation of application Ser. No. 08/299,526, filed Sep. 1, 1994, now U.S. Pat. No. 5,593,852, which is a continuation-in-part of application Ser. No. 08/161,682, filed Dec. 2, 1993, now U.S. Pat. No. 5,356,786, which is a continuation of application Ser. No. 07/664,054, filed Mar. 4, 1991, now abandoned, which applications are incorporated herein by reference.
  • [0002]
    This work was supported in part by the National Institutes of Health (DK42015). Accordingly, the U.S. government may have rights in this invention.
  • FIELD OF THE INVENTION
  • [0003]
    The present invention relates to in vivo enzyme biosensors and more specifically to miniature glucose sensors for subcutaneous measurement of glucose with one-point calibration.
  • BACKGROUND
  • [0004]
    In response to the need for frequent or continuous in vivo monitoring of glucose in diabetics, particularly in brittle diabetes, a range of possible in vivo glucose electrodes have been studied. The desired characteristics of these electrodes include safety, clinical accuracy and reliability, feasibility of in vivo recalibration, stability for at least one hospital shift of eight hours, small size, ease of insertion and removal, and a sufficiently fast response to allow timely intervention. The in vivo recalibration should be based upon withdrawal of a single sample of body fluid, e.g., blood, and measuring its glucose concentration. This is termed “one point calibration”.
  • [0005]
    Keys to safety are absence of leachable components, biocompatibility, and limiting of the potentially hazardous foreign matter introduced into the body to an amount that is inconsequential in a worst case failure. The clinical accuracy must be such that even when the readings are least accurate, the clinical decisions based on these be still correct. Feasibility of prompt confirmation of proper functioning of the sensors and of periodic in vivo recalibration is of essence if a physician is to allow the treatment of a patient to depend on the readings of the sensor. This one-point calibration, relying on the signal at zero glucose concentration being zero and measuring the blood glucose concentration at one point in time, along with the signal, is of essence, but has heretofore been elusive. The sensitivity must be sufficiently stable for the frequency of required in vivo recalibration to not be excessive. The sensor must be small enough to be introduced and removed with minimal discomfort to the patient and for minimal tissue damage. It is preferred that the sensor be subcutaneous and that it be inserted and removed by the patient or by staff in a physician's office. Finally, its response time must be fast enough so that corrective measures, when needed, can be timely.
  • [0006]
    In response to some of these needs, needle type and other subcutaneous amperometric sensors were considered. The majority of these utilized platinum-iridium, or platinum black to electrooxidize H2O2 generated by the glucose oxidase (GOX) catalyzed reaction of glucose and oxygen. In these sensors, the GOX was usually in large excess and immobilized, often by crosslinking with albumin and glutaraldehyde. To exclude electrooxidizable interferants, membranes of cellulose acetate and sulfonated polymers including Nafion™ were used. Particular attention was paid to the exclusion of the most common electrooxidizable interferants: ascorbate, urate and acetaminophen. Also to cope with the interferants, two-electrode differential measurements were used, one electrode being sensitive to glucose and electrooxidizable interferants and the other only to interferants. One strategy for overcoming the problem of interferants, applicable also to the present invention, involves their preoxidation. Another strategy involves shifting, through chemical changes, the redox potential of the polymer in the sensing layer to more reducing potentials. When the redox potential of the polymer is in the region between about −0.15 V and +0.15 V versus the standard calomel electrode (SCE), and the electrodes are poised in their in vivo operation between about −0.10 and +0.25 V, the rate of electrooxidation of interferants such as ascorbate, urate, and acetaminophen is very slow relative to that of glucose through its physiological concentration range. Thus, also the currents from electrooxidation of interferants are small relative to those of glucose.
  • [0007]
    To make the electrodes more biocompatible, hydrophilic polyurethanes, poly(vinyl alcohol) and polyHEMA membranes have been used.
  • [0008]
    Several researchers tested GOX-based glucose sensors in vivo and obtained acceptable results in rats, rabbits, dogs, pigs, sheep and humans. These studies validated the subcutaneous tissue as an acceptable glucose sensing site. Good correlation was observed between intravascular and subcutaneous glucose concentrations. They also demonstrated the need for in vivo sensor calibration. Another approach to in vivo glucose monitoring was based on coupling subcutaneous microdialysis with electrochemical detection. To control and adjust the linear response range, electrodes have been made glucose-diffusion limited, usually through glucose transport limiting membranes.
  • [0009]
    Diffusional mediators, through which the O2 partial pressure dependence of the signals is reduced, are leached from sensors. Such leaching introduces an unwanted chemical into the body, and also leads to loss in sensitivity, particularly in small sensors. In microsensors, in which outward diffusion of the mediator is radial, the decline in sensitivity is rapid. This problem has been overcome in “wired” enzyme electrodes, i.e., electrodes made by connecting enzymes to electrodes through crosslinked electron-conducting redox hydrogels (“wires”). Glucose oxidase has been “wired” with polyelectrolytes having electron relaying [Os(bpy)2Cl]+/2+ redox centers in their backbones. Hydrogels were formed upon crosslinking the enzyme and its wire on electrodes. These electrodes had high current densities and operated at a potential of 0.3V vs. SCE. The electrooxidizable interferants are eliminated through peroxidase-catalyzed preoxidation in a second, nonwired, hydrogen peroxide generating layer on the “wired” enzyme electrode.
  • SUMMARY OF THE INVENTION
  • [0010]
    A small (e.g., 0.29 mm), recessed, non-corroding metal (e.g., gold, platinum, palladium) or carbon wire electrode for subcutaneous in vivo glucose monitoring, approaching in its performance all of the above listed requirements, including in vivo one-point calibration, has been produced. The electrode was constructed by depositing active polymer layers into a recess formed by etching away gold from an insulated gold wire.
  • [0011]
    The active polymer layers, including a sensing layer, a glucose flux-limiting layer, a biocompatable layer, and optionally a peroxidase-based interferant eliminating layer, were protected within the recess against mechanical damage. (The peroxidase-based interferant eliminating layer is not required when a lower redox potential polymer is used, as described above.) The recess and its polymer layers also reduced the transport of glucose to the wire electrode contacting sensing layer.
  • [0012]
    By limiting the glucose flux, the desired linear response range, spanning the clinically relevant glucose concentration range was obtained. The inventive biosensors are able to accurately measure, for example, approximately 2-30 mμ glucose and approximately 0.5-10 mμ lactate, in vivo. The sensor has no leachable components, and its four crosslinked polymer layers contain only about 5 μg of immobilized material, and only a few nanograms of polymer-bound osmium. Preoxidation of the interferants in one of the four layers makes possible one-point in vivo calibration of the sensor.
  • BRIEF DESCRIPTION OF THE FIGURES
  • [0013]
    FIG. 1 is a schematic drawing of an electrode of the present invention.
  • [0014]
    FIG. 2 is a graphical representation of data generated comparing current density of glucose electrooxidation on electrodes made with PVI5-Os (open triangles) with those made with PVI3-Os (filled triangles).
  • [0015]
    FIG. 3 is a graphical representation of data generated comparing dependency of current generated on the depth of the recess.
  • [0016]
    FIG. 4 is a graphical representation of data generated comparing dependency of the ratio of the current generated and the charge required to electoreduce or oxidize the polymer redox centers in the sensing layer on the thickness of the sensing layer.
  • [0017]
    FIG. 5 is a graphical representation of data generated comparing variation of current generated by electrodes having sensing layers of differing thickness and diffusion limiting layers of different compositions and thickness. Solid circles: 7.5 μm thick sensing layer of PVI5-Os (52%), RGOX (35%), PEGDGE (13%), coated with 4 μm PAL/PAZ (1:1 ratio). Open circles: 5.0 sensing layer. Solid triangles: 12.5 μm sensing layer and 7 μm PAL/PAZ (1:2 ratio). Open triangles: 7.5 μm sensing layer and 4.5 μm PAL/PAZ (1:2 ratio).
  • [0018]
    FIG. 6 is a graphical representation of data generated comparing dependency of current generated on the presence of ascorbate, in the absence and presence of lactate and glucose. The concentrations of ascorbate (A), lactate (L) and glucose (G) are shown. Ascorbate is an electrooxidzable interferant. Upon addition of lactate its electrooxidation current is suppressed while that of glucose is not suppressed.
  • [0019]
    FIG. 7 is a graphical representation of data showing current density and corresponding subcutaneous glucose concentration measured with the subcutaneously implanted electrodes of the present invention in a rat animal model. Large solid circles show blood glucose concentrations measured on withdrawn blood samples using a YSI analyzer.
  • [0020]
    FIG. 8 is a Clarke-type clinical grid analyzing the clinical relevance of the blood glucose measurements of FIG. 7.
  • [0021]
    FIG. 9 is a Clarke-type clinical grid of all possible correlations obtained when each of the 24 glucose analyses of FIG. 7 were used for single point calibration of either implanted electrode.
  • [0022]
    FIG. 10 is a Clarke-type clinical grid testing improvement of the single point calibration through redundant electrodes, the readings of which were within the standard deviation calculated for all differences between simultaneous readings by a pair of implanted electrodes.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0023]
    The present invention includes an insulated, non-corroding conducting metal (e.g., gold, platinum, palladium) or carbon wire-based small (e.g., 290 μm) O.D. subcutaneous glucose sensor, allowing one-point calibration in vivo. As shown in FIG. 1, its construction involves coating a small (e.g., 250 μm) diameter non-corroding metal or carbon wire 2 with an electrically insulating material 4, e.g., a polyimide, and, layering in a recess 6 formed by etching or removing a portion of the metal or carbon, the following active polymeric layers: an immobilized, “wired,” glucose oxidase layer 8; an electrically insulating and glucose diffusion limiting layer 10 formed, for example, by crosslinking a polyallylamine (PAL) with a polyaziridine (PAZ); optionally, an interference eliminating layer 12, e.g., of crosslinked horseradish-peroxidase and lactate oxidase; and a biocompatible film 14 e.g., of poly(ethylene oxide) (PEO) derivatized to allow its photo-crosslinking. The outside diameter a of the wire 2 is preferably about 0.25 mm or less, and the outside diameter b of the insulated wire is preferably about 0.3 mm or less. The recess 6 in the insulated electrode extends from the tip 16 of the electrode which is open to the surrounding environment, to the top 18 of the wire 2 in the insulating sheath, generally for a length c of less than about 0.150 mm, and preferably about 0.125 mm.
  • [0024]
    The electrodes have no leachable components. The total amount of polymers and enzymes is preferably about 5 μg. The glucose response through the physiologically relevant 2-20 mM concentration range is close to linear. The electrodes do not respond to ascorbate, urate or acetaminophenol for at least about 36 hours. Their 10-90% response time is about 90 seconds at 2 mM glucose and about 30 seconds at 20 mM glucose. Their sensitivity, after about 30 minutes equilibration, is stable for about 72 hours at 37° C. in 10 mM glucose, the current deviating from the average by less than .±.5%. The electrodes have substantially no signal output, e.g., current, charge, or potential, when the concentration of the analyte to be measured is zero.
  • [0025]
    Two electrodes implanted subcutaneously in a rat tracked blood glucose levels, and their absolute, uncorrected current output was proportional to the blood glucose concentration. Analysis of the correlation between the blood glucose levels in the tail vein and the current output of the sensors in the subcutaneous regions of the thorax and between the scapulae of the same rat showed that even when the probed sites and organs differed in the extreme, one point in vivo calibration was valid. The analysis also showed the value of implanting redundant sensors. Had clinical decisions been made based on individual sensor readings, calibrated at one point, 94% would have been clinically correct. By using redundant sensors and accepting only those pairs of readings that were within one standard deviation, the percentage of the clinically correct decisions was increased to 99%.
  • [0026]
    It is understood that one of skill in the art may substitute various components of the biosensor described above with known materials to obtain an modified biosensor using the principles outlined herein. For example, the following substitutions are contemplated:
  • [0027]
    Base electrode: The base electrode of the inventive sensor may be formed of a non-corroding metal or carbon wire, for example vitreous carbon, graphite, platinum, palladium, or gold. Gold is preferred, and is used in the following illustrative examples of the invention.
  • [0028]
    Insulator: The conductive metal or carbon wire is coated with an electrically insulating material, which also forms a wall about the recess which houses the active polymeric components. The insulating material may be, for example, polyurethane, teflon (fluorinated polymers), polyethyleneterephthalate (PET, Dacron) or polyimide. The insulating material is preferably a biocompatible polymer containing less than about 5% water when in equilibrium with physiological body fluids, e.g., subcutaneous tissue.
  • [0029]
    Recess: In general, the recess at the tip of the electrode is approximately 20 to 150 μm in length c, and preferably is approximately 50 to 125 μm.
  • [0030]
    Etching method: The method for etching metal from the tip of the electrode described herein may utilize chloride, bromide or iodide in the bath in lieu of cyanide as described. Bromide is preferred, because it is less toxic and, like Au(CN)2 , AuBr4 is a water soluble anion. Thus, in aqueous HBR, the metal, e.g., gold, an be etched by applying a sufficiently oxidizing potential where gold is electrolytically dissolved:
    Au+4HBr→HAuBr4+(3/2)H2
  • [0031]
    Wired Enzyme Layer: In the sensing enzyme-containing layer, glucose oxidase may be substituted with other redox enzymes to measure other relevant clinical compounds. For example, lactate oxidase may be used for the in vivo detection of lactate, important in determining if an organ is receiving sufficient oxygen through the blood.
  • [0032]
    Useful redox polymers and methods for producing the sensing layer are described, for example, in U.S. Pat. Nos. 5,264,104; 5,356,786; 5,262,035, and 5,320,725. Additional redox polymers include, for example, poly(1-vinyl imidazole); poly(4-vinyl pyridine); or copolymers of 1-vinyl imidazole such as poly (acrylamide co-1-vinyl imidazole) where the imidazole or pyridine complexes with [Os (bpy)2 Cl]+/2+; [Os (4,4′-dimethyl bipyridine)2Cl]+/2+; [Os (4,4′-dimethyl phenanthroline)2Cl—]+/2+; [Os(4,4′-dimethyoxy phenanthroline)2Cl]+/2+; and [Os (4,4′-dimethoxy bipyridine)2C]+/2+; to imidazole rings. The imidazole ring compounds are preferred because their complexes have more reducing redox potentials, i.e., closer to that of the SCE potential. At these more reducing potentials, the rate of electrooxidation of interferants and the current generated thereby.
  • [0033]
    Barrier Layer: The polymeric barrier layer is electrically insulating and limits diffusion of glucose through to the sensing layer. It may be formed, for example, by crosslinking a polyallylamine (PAL) with a polyaziridine (PAZ). Alternatively, PAL may be replaced wholly or in part with a zwitterionic polymer obtained by quaternizing poly(vinylpyridine) with bromoacetate and dialyzing against 0. 15M NaCl or by a polyanion such as a polysulfonic acid.
  • [0034]
    The barrier layer may contain a polyanionic polymer, in which the rate of permeation of anionic interferants such as ascorbate and urate is slowed. This layer may also contain a polycation that enhances the retention of the polyanion by electrostatic bonds and improves wetting by the biocompatable layer.
  • [0035]
    Interference Eliminating Layer: As described above, this layer is optional, in that it is not required when a redox polymer having a more reducing potential is used, such as PVI15-dmeOs (Ohara et al., Analytical Chemistry, 1994, 64:2451-2457). At operating potentials of approximately −0.10 to +0.25 for the glucose biosensor, the rate of electrooxidation of interferants such as ascorbate, urate and acetaminophen is very slow relative to that of glucose through its physiological concentration range.
  • [0036]
    When a separate interferant eliminating layer is used, it preferably contains a peroxidase enzyme which may or may-not be preactivated. Such interferant eliminating layers are disclosed, for example, in U.S. Pat. No. 5,356,786, which discloses the structure and function of interferant eliminating biosensors. The glucose biosensor preferably contains lactate oxidase (LOX) in combination with peroxidase in the interferant eliminating layer. However, for biosensors used to detect lactate, glucose oxidase would be used with peroxidase. In a similar manner, the enzyme composition of the interferant eliminating layer may be altered for a specified function.
  • [0037]
    Biocompatable Layer: In general, the biocompatable layer is comprised of hydrogels, e.g., polymeric compositions which contain more than about 20% by weight of water when in equilibrium with a physiological environment such as living tissue or blood. An example is crosslinked poly(ethylene oxide), e.g., poly(ethylene oxide) tetraacrylate. The polymeric compositions must be non-toxic and compatible with living Systems.
  • [0038]
    Method for making multi-layered recessed biosensors: Insulated non-corroding metal or carbon wires that have been etched as described above to contain a recess at the tip, are placed in a block that serves as an X-Y positioner. The wires vertically traverse the block and are held in place, e.g., by pressure. The blocks with the wires can be formed of elements, each element having multiple half-cylinder grooves running vertically. The wires are placed in these grooves and the elements are assembled into the block using screws. For example, the block may be formed of aluminum having equally spaced holes, (900 for a 30×30 array of wires), each hole to contain one wire. The block is positioned under a fixed micronozzle that ejects a fluid in to the recess of the insulated wire.
  • [0039]
    To reduce the requirement of precision in the positioning of the block and the micronozzle, the nozzle is electrically charged, with the wire having an opposite charge, or the wire being grounded or at least having a potential such that there is a potential difference between the nozzle and the wire. Because the nozzle is charged, the microdroplets it ejects are also charged with the same type of charge (positive or negative) as the nozzle. The higher the potential on the nozzle (e.g., versus ground potential), the higher the charge on the ejected microdroplets. If the tip of the wire to be coated is at ground potential or has a charge of the opposite type, the charged microdroplets are guided into the recess to deposit on the electrode, even if the jet of microdroplets is not vertical, i.e., even if the micronozzle is not precisely aligned above the wire's tip.
  • [0040]
    Furthermore, the higher the electrical potential on the nozzle (relative to ground) the greater the charge on the ejected microdroplet. When the charge is high enough, the droplet breaks up into two or more smaller droplets because of electrostatic repulsion of charges on the droplet. Thus, the very small droplets all “drift” (drift meaning transport assisted by an electrical field) to the recessed electrode surface and are collected on it, even if they did not originate in a nozzle precisely aligned with the electrode.
  • [0041]
    This coating method is useful in making any small biosensor, not only those in recessed zones.
  • [0042]
    Clinical Use of the Recessed Biosensors:
  • [0043]
    The recessed biosensors of the present invention have sufficient sensitivity and stability to be used as very small, subcutaneous biosensors for the measurement of clinically relevant compounds such as glucose and lactate. The electrodes accurately measure glucose in the range of about 2-30 μM and lactate in the range of about 0.5-10 mM. One function of the implanted biosensor is to sound an alarm when, for example, a patient's glucose concentration is too low or too high. When pairs of implanted electrodes are used, there are three situations in which an alarm is triggered: low glucose concentration, high glucose concentration; sensor malfunction as determined by a discrepancy between paired readings of the two sensors. A discrepancy sufficient to trigger the alarm may be, for example more than two or three times the standard deviation persisting for a defined period, e.g., not less than ten minutes. Such a system may be useful in sleeping patients, and also in emergency and intensive care hospital rooms, where vital functions are continuously monitored.
  • [0044]
    Another function of the inventive biosensors in to assist diabetics in maintaining their blood glucose levels near normal. Many diabetics now maintain higher than normal blood glucose levels because of danger of coma and death in severe hypoglycemia. However, maintaining blood glucose levels substantially, e.g., approximately 40% or more above normal leads to retinopathy and blindness as well as to kidney failure. Use of the subcutaneous biosensors to frequently, if not continuously, monitor glucose concentrations is desirable so that glucose concentrations can be maintained closer to an optimum level.
  • [0045]
    The subcutaneous biosensors can be used to measure the rate of rise and decline of glucose concentrations after a meal or the administration of glucose (e.g., a glucose tolerance test). The sensors are also useful in feedback loops for automatic or manually controlled maintenance of glucose concentrations within a defined range. For example, when used in conjunction with an insulin pump, a specified amount of insulin is delivered from the pump if the sensor glucose reading is above a set value.
  • [0046]
    In all of these applications, the ability to promptly confirm that the implanted sensor reading is accurate is essential. Prompt confirmation and rapid recalibration are possible only when one-point calibration is valid. Generally, even if a sensor's response is linear through the relevant concentration range, calibration requires at least two blood or fluid samples, withdrawn from the patient at times when the glucose concentration differs. It usually takes several hours for the glucose concentration to change sufficiently to validate proper functioning by two-point calibration. The ability to confirm and recalibrate using only one point is thus a highly desirable feature of the present invention.
  • [0047]
    Redundant sensors (e.g., at least two) are preferred in the clinical application of the subcutaneous biosensors. Such redundancy permits signaling of failure of any one sensor by recognition of an increase in the discrepancy between the readings of the sensors at one time point, e.g., more than two standard deviations apart. The redundant sensors may be implanted near each other or at remote sites.
  • [0048]
    It is preferred that the biosensors be implanted in subcutaneous tissue so as to make the sensor relatively unobtrusive, and at a site where they would not be easily dislodged, e.g., with turning or movement. It is also preferred, when readings are not corrected for temperature (which they generally are) that the sensors be implanted where they are likely to be at body temperature, e.g., near 37° C., and preferably covered by clothing. Convenient sites include the abdomen, inner thigh, arm.
  • [0049]
    Although we describe here continuous current measurement for assaying glucose, the electrical measurement by which the glucose concentration is monitored can be continuous or pulsed. It can be a current measurement, a potential measurement or a measurement of charge. It can be a steady state measurement, where a current or potential that does not substantially change during the measurement is monitored, or it can be a dynamic measurement, e.g., one in which the rate of current or potential change in a given time period is monitored. These measurements require at least one electrode in addition to the sensing electrode. This second electrode can be placed on the skin or can be implanted, e.g., subcutaneously. When a current is measured it is useful to have a potentiostat in the circuit connecting the implanted sensing electrode and the second electrode, that can be a reference electrode, such as an Ag/AgCl electrode. When a current is measured the reference electrode may serve also as the counter electrode. The counter electrode can also be a separate, third electrode, such as a platinum, carbon, palladium or gold electrode.
  • [0050]
    In addition to implanting the sending electrode in the body, fluid from the body, particularly fluid from the subcutaneous region, can be routed to an external sensor. It is preferred in this case to implant in the subcutaneous region a microfiltration giver and pull fluid to an evacuated container, the fluid traversing a cell containing the sensing electrode. Preferably this cell also contains a second electrode, e.g., a reference electrode which may serve also as a counter electrode. Alternatively, the reference and counter electrodes may be separate electrodes. In coulometric measurements only two electrodes, the sensing electrode and the counter electrode are required. The flow of body fluid may be pulsed or continuous. Other than an implanted microfiltration fiber, also a microdialysis fiber may be used, preferably in conjunction with a pump.
  • [0051]
    Increased Stability of the Biosensors:
  • [0052]
    To increase the stability and useful life of the inventive biosensors, it is advantageous to use intrinsically more stable enzymes and redox polymers. However, even if the enzyme and redox polymer degrade in the glucose electrooxidation process by which the signal (current) is generated, it is possible to greatly extend the useful life of the implanted electrodes and reduce the frequency of their required recalibration after implantation.
  • [0053]
    A simple measure by which the life of the implanted electrodes can be extended and the frequency of their required recalibration reduced involves turning the electrodes “on” by applying a bias, i.e., a potential, only during the period of measurement, then turning the biasing potential off or reducing it, so that a lesser current will flow. It is generally sufficient to perform only one measurement every five or even ten minutes, or longer, because glucose concentrations do not change abruptly.
  • [0054]
    Another measure is to lower the glucose flux to the sensing layer much as possible, consistent with maintaining adequate sensitivity and detectivity. Reduction of the glucose flux to the sensing layer reduces the current. Therefore, even though this stabilizes the electrodes, i.e., slows the loss in sensitivity, the flux dependent current must not be excessively reduced. Usually a current of 3-5 nA at 2 mM glucose concentration is adequate. When the glucose flux is lowered by using one or more glucose-flux reducing polymer slayers, such as the PAL/PAZ layer, the lifetime of the sensor is increased.
  • EXAMPLES Example 1
  • [0055]
    Electrode Preparation
  • [0056]
    Electrodes were made of a polyamide-insulated 250 μm diameter gold wire, having an outer diameter (O.D.) of 290 μm (California Fine Wire Co., Grover City, Calif.). Heat shrinkable tubing (RNF 100 3/64″ BK and 1/16″ BK, Thermofit.RTM., Raychem, Menlo Park, Calif.) and a two component silver epoxy (Epo-tek H2OE; Epoxy Tech, Inc., Billerica, Mass.) were used for electrode preparation.
  • [0057]
    The glucose sensing layer was made by crosslinking a genetically engineered glucose oxidase (rGOX) (35% purity, Chiron Corp., Emeryville, Calif.) with a polymer derived of poly(vinylimidazole) (PVI), made by complexing part of the imidazoles to [Os(bpy)2C]+/2+. The resulting redox polymer, termed PVI-Os, was synthesized -according to a previously published protocol. (Ohara et al., 1993, Anal. Chem., 65:24). Poly(ethylene glycol) diglycidyl ether 400 (PEDGE; Polysciences, Warrington, Pa.) was used as the crosslinker.
  • [0058]
    The barrier layer between the sensing and interference-eliminating layers was made of polyallylamine (PAL; Polysciences) crosslinked with a polyfunctional aziridine (PAZ) (XAMA-7; Virginia Chemicals, Portsmouth, Va.).
  • [0059]
    The interference-eliminating layer was prepared by co-immobilizing horseradish peroxidase (HRP) type VI (Cat. No. P-8375, 310 U/mg, denoted herein as HRP-VI, Sigma, St. Louis, Mo.) and HRP for immunological assay (No. 814407, min 1000 U/mg, denoted HRP-BM, Boehringer-Mannheim, Indianapolis, Ind.) with lactate oxidase from Pediococcus sp. (Cat. No. 1361, 40 U/mg denoted LOX, Genzyme, Cambridge, Mass.) and a recombinant microbial source (Cat. No. 1381 denoted rLOX, Genzyme). Co-immobilization was performed using sodium periodate (Cat. No. S-1 147, Sigma) according to the methods described in Maidan and Heller, 1992, Anal. Chem. 64:2889-2896.
  • [0060]
    The biocompatible layer was made of 10% aqueous poly(ethylene oxide) tetraacrylate (PEO-TA). To form the photocrosslinkable polymer, PEO was acrylated by reaction with acryloyl chloride. The 18,500 g/mol PEO (Polysciences) is a tetrahydroxylated compound by virtue of two hydroxyl groups on a bisphenol A bisepoxide that linked two alpha., .omega.-hydroxy-terminated 9,000 g/mol PEO units. Acryloyl chloride (Aldrich, Milwaukee, Wis.) in a 2 to 5 molar excess was used to acrylate the polymer (10% w/v PEO in benzene). Triethylamine (Mallinkrodt, Paris, Ky.) was used as a proton acceptor equimolar with theacryloyl chloride.
  • [0061]
    Other chemicals used were bovine serum albumin (BSA) fraction V (Cat. No. A-2153), BSA, ascorbic acid, uric acid, 4-acetaminophenol, L(+)=lactic acid, and hydrogen peroxide 30%., all from Sigma. All chemicals were used as received. Solutions (if not otherwise specified) were made with distilled, deionized water. Glucose monitoring was performed in buffer, in bovine serum (Sigma, Cat. No. S-6648) containing antibiotic-antimycotic solution (Sigma, Cat. No. A-8909) at 37° C. and in rats.
  • [0062]
    Instrumentation
  • [0063]
    In making the recessed gold electrodes, a potentiostat/galvanostat (PAR Model 173, Princeton Applied Research, Princeton, N.J.) operated in a galvanostatic mode, and a sonicator (Fisher scientific, Pittsburgh, Pa.) were used. Cyclic voltammograms were recorded with a potentiostat (PAR Model 273A) and a conventional electrochemical cell having a Pt wire counter and a SCE reference electrode and were evaluated with PAR 270 software. Glucose signals were monitored with a bipotentiostat (Biometra EP 30) and a two channel strip-chart recorder. The recessed electrodes were coated under a microscope (Bausch & Lomb) using a micromanipulator (Narishige, Seacliff, N.Y.). The micropipettes were pulled with a micropipette puller (Narishige). Temperature was controlled with an isothermal circulator (Fisher Scientific).
  • [0064]
    Electrode Preparation:
  • [0065]
    Five cm lengths of polyamide insulated gold wire were cut with a sharp razor blade. Electrical contact was made at one end with silver epoxy to an insulated stainless steel wire and the junction was covered with insulating heat shrinkable tubing. The recess forming electrochemical etching process was carried out in 10 ml of 3M potassium cyanide, with the gold wire as the working electrode and a platinum or gold wire as the counter electrode. The wires were placed in contact with the bottom of the beaker, all electrodes being equidistant from the counter electrode. The beaker was sonicated during the etching procedure. The ends of the gold wires were bent upwards, so that agitation by the sonicator caused the oxygen bubbles formed during the etching process to rise and escape. The electrodes were then thoroughly washed and immersed in water for 30 minutes.
  • [0066]
    A recess 6, i.e., channel, in a polyamide insulated gold wire 2 is formed by electrochemical etching of the gold under galvanostatic control. By controlling the charge, the total amount of gold electrooxidized and dissolved as Au(CN)2 is defined.
  • [0067]
    When the conditions were set so that the CN—transport into the channel and the Au(CN)2— transport out of it are not rate limiting, (e.g., sonicated bath and high concentration of potassium cyanide, at least approximately 0.2M, and preferably 3M), a flat gold wire surface is produced at the bottom of channels with aspect ratios of 0.5 to 2.0. Thus, when the CN—concentration is high enough and the wires are ultrasonically vibrated, the tips of gold wires are flat. Passage of 1.5 coulombs per electrode at 8 mA current produced approximately 125 Jim deep cavities or channels. At theoretical efficiency for one-electron oxidation, 3.08 mg of gold would have been etched. The amount of gold actually etched was only 0.076 mg, showing significant CN—or water oxidation.
  • [0068]
    Nevertheless, the process is reproducible, accurate and fast with 20 electrodes being processed in each batch in less than five minutes. The recess-forming procedure was highly reproducible, with a deviation of ±10 μm found (using an objective micrometer) for a batch of 30 recessed electrodes. Before coating, the electrodes were examined under a microscope for flatness of the gold surface and correct depth.
  • [0069]
    FIG. 1 shows a schematic side view in cross-section of an electrode of the present invention, showing the gold wire 2, insulating coating 4, and recess or channel 6. The recessed gold surfaces were coated by filling of the cavities or channels 6 with aqueous solutions containing the crosslinkable components of the different layers, and their crosslinkers. The solutions were introduced under a microscope with a micropipette (connected to a microsyringe by polyethylene tubing and shrink tubing), using a micromanipulator. After application of each of the individual layers, the electrodes were cured overnight at room temperature, in air.
  • [0070]
    Electrode Structure:
  • [0071]
    The electrodes were prepared by sequentially depositing four layers within the recess or channel 6. The layers were: the sensing layer 8, the insulating layer 10, the interference-eliminating layer 12 and the biocompatible layer 14. The sensing layer, containing “wired” redox enzyme is positioned adjacent to and in contact with the gold wire 2. The insulating layer 10 is positioned between the sensing layer 8 and the peroxidase-based interferant-eliminating layer 12. The biocompatible layer 14 fills the remaining space in the recess 6 and is in contact with the environment outside the electrode. The thin polymer layers are well protected by containment within the polyamide sleeve 4.
  • [0072]
    The sensing layer 8 was made by “wiring” rGOX to the gold electrode through a redox hydrogel to which the enzyme was covalently bound. The electrodes were prepared as follows: 10 mg/ml solutions were made from
  • [0073]
    1. the PVI-Os redox polymer in water,
  • [0074]
    2. the crosslinker, PEGDGE, in water, and
  • [0075]
    3. the enzyme, rGOX, in a 10 mM HEPES solution adjusted to pH 8.15.
  • [0076]
    A redox hydrogel was formed by mixing the three solutions so that the final composition (by weight) was 52% redox polymer, 35% enzyme and 13% crosslinker.
  • [0077]
    The insulating layer 10 prevented electrical contact between the redox hydrogel and the interference eliminating enzymes (HRP and LOX). PAL:PAZ was used as the insulating material. The film was deposited from a solution obtained by mixing in volume ratio of 1/1, ½ or ⅓, a PAL solution (4.5 mg in 100 mM HEPES buffer at pH 7.0) and a freshly prepared PAZ solution (30 mg/ml). The PAZ solution was used within 15 minutes of preparation.
  • [0078]
    The interference-eliminating layer 12 was prepared according to a previously published protocol, Maidan and Heller, 1992, Anal. Chem., 64:2889-2896. 50 μl of a 12 mg/ml freshly prepared sodium periodate solution was added to 100 μl of a solution containing 20 mg/ml HRP (HRP-VI or HRP-BM) and 100 mg/ml LOX (LOX or rLOX) in 0.1 M sodium bicarbonate and the mixture was incubated in the dark for two hours. Alternatively, the oxidation of HRP could be carried out prior to adding LOX and cross linking.
  • [0079]
    The biocompatible layer 14 films were photocrosslinked by exposure to UV light (UVP, Inc., San Gabriel, Calif.; Blak-Ray; spectral peak at 360 nM UV irradiance at the sample 200 mW/cm2) for one minute. The initiator used was 2,2-dimethoxy-2-phenylacetophenone (Aldrich). A solution of 300 mg/ml of the initiator in 1-vinyl-2-pyrrolidinone (Aldrich) was added to the prepolymer mixtures. Approximately 30 μl of the initiator solution was added per ml of 10% w/w aqueous solution of the tetraacrylated PEO. The prepolymers were crosslinked in situ inside the recess of the electrode. The films were prepared by filling the recess with the prepolymer solution twice and exposing the electrode to the UV light source after each time the cavity was filled.
  • [0080]
    In Vitro Testing of Electrodes:
  • [0081]
    In vitro experiments were carried out in batch fashion at 250 and 37° C., using a conventional three electrode electrochemical cell with the enzyme-modified gold wire as the working electrode, a platinum wire as the counter electrode and a saturated calomel reference electrode (SCE). The electrolyte was a 20 mM phosphate buffered-saline solution containing 0.15 M NaCl at pH 7.15. Experiments in serum were performed at 37° C., adding 100 μL antibiotic-antimycotic solution to 10 ml serum. Phosphate buffered-saline and serum were agitated during the experiments. The working potential was +0.3 V versus SCE for experiments with the PVI-Os polymers.
  • [0082]
    Structure and Performance: The depth c of the channel 6 and the thickness of the polymer layers in it controls the mass transport, i.e., flux of glucose, to the sensing layer. By controlling these parameters, the apparent Michaelis constant (Km) is adjusted to about 20-30 mM glucose. The polyimide wall 4 of the channel 6 also protects the four polymer and polymer/enzyme layers 8, 10, 12, 14 against mechanical damage and reduces the hazard of their loss in the body. Because the glucose electrooxidation current is limited by glucose mass transport through the recess 16 and its polymer films 8, 10, 12, 14, rather than by mass transport to the tissue-exposed tip 16, the current is practically insensitive to motion. Evidently, the electrooxidation rate of glucose in the recessed sensing layer 8 is slower than the rate of glucose diffusion to the channel's outer fluid contacting interface.
  • [0083]
    PVI5-Os is preferred as the “wire” of the sensing layer when an interference eliminating layer of HRP and LOX is used, but not in the absence of this layer, i.e., when redox polymers with more reducing redox potential are preferred. The subscript (5) is used to indicate that, on the average, every fifth vinylimidazole mer carries an electron-relaying osmium center. Use of electrodes formed with PVI5-Os and PVI3-Os (every third 1-vinylimidazole mer carrying an osmium center) are compared in FIG. 2, and show higher current density of glucose electrooxidation on electrodes made with PVI5-Os (open triangle) than on those made with PVI3-Os (filled triangles).
  • [0084]
    Depth of the recess and the sensing layer: Channels of 125, 250, and 500 μm depth, were investigated to assess the dependence of the current on the depth of the recess (FIG. 3), with the total amount of PVI5-Os and rGOX being kept constant. Much of the loss in current in the deeper cavities resulted not from reduced glucose mass transport, but from adsorptive retention of part of the enzyme and polymer on the polyamide wall when microdrops of the component solutions were introduced into the recess in the process of making the electrodes. Through repeated rinsing with water, some of the adsorbed polymer and enzyme on the walls were washed onto the electrode surface, increasing the current. The highest currents were seen after five washings. When the thickness of the sensing layer was increased through increasing the number of coatings (FIG. 4) the ratio of current to charge required to electroreduce or electrooxidize the redox polymer in the sensing layer reached a maximum, then dropped. For the preferred 125 μm recess, 10 coatings, producing an approximately 13 Am thick wired-rGOX sensing layer, yielded sensors that had the desired characteristics for in vivo use.
  • [0085]
    The insulating layer: This layer electrically insulates the redox enzymes of the interference eliminating layer (HRP and LOX) from the “wired” rGOX layer and limits the glucose flux to the sensing layer, thereby extending the useful life of the electrode. PAL crosslinked with PAZ, forming a polycationic network at pH 7.09 is preferred. The best results, i.e., best stability of current outputs, were obtained using 1:2 PAL:PAZ (FIG. 5), with three coatings applied to form an approximately 7 μm thick crosslinked film.
  • [0086]
    The interference eliminating layer: Interferants, particularly ascorbate, urate, and acetaminophenol, are oxidized in the third layer, containing LOX and HRP. In this layer, lactate, the typical concentration of which in blood is 1 mM, reacts with O2 to form H2O2 and pyruvate. H2O2, in the presence of HRP, oxidizes ascorbate, urate, and acetaminophenol, being reduced to water. The preferred coimmobilization process involved two separate steps: periodate oxidation of oligosaccharide functions of HRP to aldehydes, followed by mixing with LOX and formation of multiple Schiff bases between HRP-aldehydes and LOX amines (e.g. lysines) and between HRP aldehydes and amines. The thickness of the interference eliminating layer is approximately 85 μm and is made by applying successive coatings, e.g., about six coatings. FIG. 6 shows that electrooxidizable interferants were eliminated in the presence of lactate at physiological levels. LOX slowly lost its activity in the crosslinked HRP-LOX layer. This led to degradation of the ability of the layer to eliminate interferants. After 36 hours of operation at 37° C., a measurable current increment was noted when enough ascorbate was added to produce a 0.1 mM concentration.
  • [0087]
    The biocompatible layer: A preferred biocompatible layer consists, for example, of photocrosslinked tetraacrylated 18,500 Da poly(ethylene oxide) (Pathak et al., 1993, J. Am. Chem. Soc., 114:8311-8312). The thickness of this layer, made by sequential photo-crosslinking of two coatings, is about 20 μm. One minute UV exposure required for the photocrosslinking process reduced the sensitivity by 16±2%.
  • Example 2
  • [0088]
    In Vivo Use of Sensor
  • [0089]
    The objective of this experiment was to establish the validity of a one-point in vivo calibration. Two sensors were simultaneously implanted subcutaneously in a rat, one on the thorax, the second between the scapulae. To make the difference between the blood sampled and the subcutaneous fluid proved with the sensors as extreme as possible, i.e., to probe whether the one-point calibration holds even if the organs sampled are different and the sampling sites are remote, blood was withdrawn from the tail vein. Blood glucose levels were periodically measured in withdrawn samples, while the absolute uncorrected sensor current output was continuously monitored.
  • [0090]
    In vivo experiments (6-10 hours) were carried out in 300 g male Sprague-Dawley rats. The rats were fasted overnight and prior to the experiment were anaesthetized with an intraperitoneal (i.p.) injection of sodium pentobarbital (65 mg/kg rat wt). An i.p. injection of atropine sulfate (166 mg/kg rat wt) was then administered to suppress respiratory depression. Once the rat was anaesthetized, a portion of the rat's abdomen was shaved, coated with a conductive gel, and an Ag/AgCl surface skin reference electrode was attached. This electrode served also as the counter electrode. Sensors were then implanted subcutaneously using a 22 gauge Per-Q-Cath Introducer (Gesco International, San Antonio, Tex.) on the rat's thorax, or subcutaneously in the intrascepular area through a small surgical incision. The sensors were taped to the skin to avoid sensor movement. The sensors, along with the reference electrode, were connected to an in-house built bipotentiostat. The operating potential of the sensors was 0.3 V vs. Ag/AgCl, with the Ag/AgCl electrode serving as both the reference counter electrode. Sensor readings were collected using a data logger (Rustrak Ranger, East Greenwich, R.I.) and at the end of the experiment were transferred to a computer. During the experiment, the rat's body temperature was maintained at 37° C. by a homeostatic blanket. The sensors were allowed to reach a basal signal level for at least one hour before blood sampling was started. Blood samples were obtained from the tail vein and all blood samples were analyzed using a glucose analyzer (YSI, Inc., Yellow Springs, Ohio; Model 23A).
  • [0091]
    Approximately thirty minutes after the start of blood sampling, an i.p. glucose infusion was started using a syringe pump (Harvard Apparatus, South Natick, Mass.) at a rate of 120 mg glucose/min kg rat wt. The glucose infusion was maintained for approximately one hour.
  • [0092]
    As seen in FIG. 7, at 410 min the current dropped precipitously. Such a drop was observed in other measurements with subcutaneously implanted electrodes between 400 and 600 min, but was never observed in electrodes operated in buffer at 37° C. When the failed electrodes were withdrawn and retested in buffer, most of their original sensitivity was found to be intact. The cause for this apparent deactivation was failure of the counter/reference Ag/AgCl electrode on the rat's skin to make good electrolytic contact, and was not due to any failure of the implanted sensor. Using an arbitrarily chosen point to calculate a calibration curve for each electrode, i.e., one blood glucose level determination and one current measurement to establish the scales, all the data from FIG. 7 were plotted in a Clarke-type, (Clarke et al., 1987, Diabetes Care, 5:622-627) clinical grid (FIG. 8), without further correction. In this analysis, points falling in region A of the grid are considered clinically accurate, while those in region B are considered clinically correct. Points falling in region C are not correct, but would not lead to improper treatment. Points in regions D and E are incorrect and if treatment would rely on these, it would be improper.
  • [0093]
    All of the points, from both electrodes, were in regions A and B, with 43 of the 48 points being in region A. The three points in region B near 100 mg/dl glucose, for the electrode implanted between the scapulae, were the last three points of the experiment, at about 410 min. Notwithstanding the failure mode at 400-600 min because of poor electrolytic contact of the counter/reference electrode with the skin and failure after 36 hours by deactivation of the lactate oxidase, resulting in loss of interference elimination, one-point calibration is shown here to be practical. After such calibration, the readings of the subcutaneous sensors provide, without any correction, clinically useful estimates of blood glucose levels.
  • [0094]
    FIG. 9 shows the distribution of all possible. correlations obtained when each of the 24 glucose analyses was used for single point calibration of either implanted electrode. There are 2×24×24=1152 points in the distribution. Of these, 78% are in region A, 15% are in region B, 1% in region C, 6% are in region D, and no points are in region E.
  • [0095]
    In FIG. 10, we tested for the improvement of the single point calibration through using redundant electrodes. First, the readings of electrode A were normalized with respect to those of electrode B by multiplying each reading by the average output of electrode B divided by the average output of electrode A. Next the standard deviation was calculated for the differences between the 24 sets of readings of implanted electrode B and corrected readings of implanted electrode A. Then, all those sets of readings that differed by more than the standard deviation were rejected. The number of sets was reduced thereby from 24 to 11; 82% of the points were in region A, 17% in region B, 1% in region D, and no points in regions C and E. The distribution demonstrates that the sensors can be calibrated through a single independent measurement of the glucose concentration in a withdrawn blood sample. They also demonstrate the improvement in clinical accuracy resulting from the use of redundant subcutaneous sensors. The selection of those data points that differed by less than the standard deviation for the entire set led to a sixfold reduction in the probability of clinically erring in a decision based on readings of the implanted sensors.
  • [0096]
    Stability and Other Characteristics:
  • [0097]
    In order to improve the stability, more thermostable recombinant GOX, (rGOX; Heller, 1992, J. Phys. Chem., 96:3579-3587) rather than GOX is used in the sensor and glucose transport is reduced to make the sensor current diffusion, not enzyme turnover, limited. The glucose flux is attenuated by the three outer layers and the sensing layer itself. Because the sensing layer contains a large excess of glucose oxidase, its activity greatly exceeds that needed for electrooxidizing the attenuated glucose flux, and the sensor's stability is improved.
  • [0098]
    The stability can be tested by methods known, for example, tested in the presence of 0.1 mM ascorbate in 10 mM glucose at 37° C. The current output of a typical optimized electrode was about 35 nA and the apparent Km, derived from an Eadie-Hofstee plot, was about 20 mM (Table 1). The 10-90% response time was approximately one minute.
  • [0099]
    As expected, and as can be seen in FIG. 5, with thinner films the glucose mass transport was increased, i.e., the current was higher, while for thicker films the stability was improved. Because of the high sensitivity of thin sensing film (approximately 1 μm) electrodes (less than 10−2A cm−2 M−1), an order of magnitude decrease in sensitivity could be traded for stability, while the currents remained high enough to be easily measured.
  • [0100]
    As seen in FIG. 5, the sensitivity of the stabilized sensors does not change by more than +5% for 72 hours of operation at 37° C. After a small initial decrease in sensitivity, it increased to a maximum after 40 hours and the final 72 hour sensitivity was almost identical with the initial.
  • [0101]
    The characteristics of the electrodes of the present invention are summarized in Table 1. Each entry represents an average value for five tested electrodes. Baseline currents are typically less than 0.5 nA and the noise less than 10 pA. The currents observed throughout the physiological glucose concentration range (2-20 mM) exceed the noise equivalent current by at least a factor of 100. The apparent Km is 20 mM, and the 10% to 90% response time is, for aged electrodes, about 90 seconds at the lowest physiologically relevant glucose concentration (2 mM) and 20 seconds at the highest (20 mM).
  • [0102]
    The baseline of nil at 0 mM glucose is stable for 36 hours in the presence of 0.1 mM ascorbate. The stability observed and the existence of a valid zero-point in the presence of interferants suggest that the sensor can be used in vivo for 72 hours and tested/recalibrated in vivo through a single point calibration, i.e., by withdrawing only a single sample of blood for independent analysis.
    TABLE 1
    SENSOR CHARACTERISTICS
    Current
    Km app (mM) Km app (mM) Variance
    i (nA) j (μA/cm2) EH LB tr (s) (%)
    33.9 69.1 18.5 33.4 30-90 5.0

    where:

    I is the current measured at 37° C. and at 10 mM glucose concentration

    j is the current density measured at 37° C. at 10 mM glucose concentration

    KM app is the apparent Michaelis-Menten coefficient determined from an electrochemical Eadie-Hoffstee (EH) or Lineweaver-Burk (LB) plot

    tr is the 10-90% risetime, 90 s for 2 mM and 30 s for 20 mH glucose concentration.

    Current Variance is the maximum deviation from the mean value, measured during the 72 hour test, conducted in 10 mM glucose in the presence of interferants. The current was continuously monitored at 37° C.
  • [0103]
    The foregoing examples are designed to illustrate certain aspects of the present invention. The examples are not intended to be comprehensive of all features and all embodiments of the present invention, and should not be construed as limiting the claims presented herein.
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US4008717 *5 mars 197622 févr. 1977The Johns Hopkins UniversitySystem for continuous withdrawal and analysis of blood
US4076596 *7 oct. 197628 févr. 1978Leeds & Northrup CompanyApparatus for electrolytically determining a species in a fluid and method of use
US4184429 *29 janv. 197622 janv. 1980Max Datwyler & Co.Constant bevel doctor blade and method and apparatus using same
US4247297 *23 févr. 197927 janv. 1981Miles Laboratories, Inc.Test means and method for interference resistant determination of oxidizing substances
US4425920 *24 oct. 198017 janv. 1984Purdue Research FoundationApparatus and method for measurement and control of blood pressure
US4427770 *14 juin 198224 janv. 1984Miles Laboratories, Inc.High glucose-determining analytical element
US4431004 *27 oct. 198114 févr. 1984Bessman Samuel PImplantable glucose sensor
US4494950 *19 janv. 198222 janv. 1985The Johns Hopkins UniversityPlural module medication delivery system
US4571292 *12 août 198218 févr. 1986Case Western Reserve UniversityApparatus for electrochemical measurements
US4633878 *10 avr. 19846 janv. 1987Guiseppe BombardieriDevice for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal
US4637403 *14 juin 198520 janv. 1987Garid, Inc.Glucose medical monitoring system
US4717673 *19 nov. 19855 janv. 1988Massachusetts Institute Of TechnologyMicroelectrochemical devices
US4721601 *23 nov. 198426 janv. 1988Massachusetts Institute Of TechnologyMolecule-based microelectronic devices
US4721677 *7 mai 198726 janv. 1988Children's Hospital Medical CenterImplantable gas-containing biosensor and method for measuring an analyte such as glucose
US4726378 *11 avr. 198623 févr. 1988Minnesota Mining And Manufacturing CompanyAdjustable magnetic supercutaneous device and transcutaneous coupling apparatus
US4726716 *21 juil. 198623 févr. 1988Mcguire Thomas VFastener for catheter
US4795707 *25 nov. 19853 janv. 1989Hitachi, Ltd.Electrochemical sensor having three layer membrane containing immobilized enzymes
US4796634 *9 août 198510 janv. 1989Lawrence Medical Systems, Inc.Methods and apparatus for monitoring cardiac output
US4805624 *14 avr. 198721 févr. 1989The Montefiore Hospital Association Of Western PaLow-potential electrochemical redox sensors
US4805625 *8 juil. 198721 févr. 1989Ad-Tech Medical Instrument CorporationSphenoidal electrode and insertion method
US4890620 *17 févr. 19882 janv. 1990The Regents Of The University Of CaliforniaTwo-dimensional diffusion glucose substrate sensing electrode
US4894137 *14 sept. 198716 janv. 1990Omron Tateisi Electronics Co.Enzyme electrode
US4897162 *2 févr. 198830 janv. 1990The Cleveland Clinic FoundationPulse voltammetry
US4897173 *19 juin 198630 janv. 1990Matsushita Electric Industrial Co., Ltd.Biosensor and method for making the same
US4898591 *9 août 19886 févr. 1990Mallinckrodt, Inc.Nylon-PEBA copolymer catheter
US4986271 *19 juil. 198922 janv. 1991The University Of New MexicoVivo refillable glucose sensor
US4994167 *7 juil. 198819 févr. 1991Markwell Medical Institute, Inc.Biological fluid measuring device
US4995402 *12 oct. 198826 févr. 1991Thorne, Smith, Astill Technologies, Inc.Medical droplet whole blood and like monitoring
US5082550 *11 déc. 198921 janv. 1992The United States Of America As Represented By The Department Of EnergyEnzyme electrochemical sensor electrode and method of making it
US5082786 *28 nov. 198821 janv. 1992Nec CorporationGlucose sensor with gel-immobilized glucose oxidase and gluconolactonase
US5089112 *11 janv. 199018 févr. 1992Associated Universities, Inc.Electrochemical biosensor based on immobilized enzymes and redox polymers
US5184619 *2 oct. 19879 févr. 1993Peritronics Medical, Inc.Intrauterine pressure and fetal heart rate sensor
US5279294 *26 mars 199018 janv. 1994Cascade Medical, Inc.Medical diagnostic system
US5285792 *10 janv. 199215 févr. 1994Physio-Control CorporationSystem for producing prioritized alarm messages in a medical instrument
US5286362 *27 avr. 199315 févr. 1994Boehringer Mannheim GmbhMethod and sensor electrode system for the electrochemical determination of an analyte or an oxidoreductase as well as the use of suitable compounds therefor
US5286364 *29 mars 199115 févr. 1994Rutgers UniversitySurface-modified electochemical biosensor
US5288636 *14 déc. 199022 févr. 1994Boehringer Mannheim CorporationEnzyme electrode system
US5378628 *19 févr. 19923 janv. 1995Asulab, S.A.Sensor for measuring the amount of a component in solution
US5387327 *19 oct. 19927 févr. 1995Duquesne University Of The Holy GhostImplantable non-enzymatic electrochemical glucose sensor
US5390671 *15 mars 199421 févr. 1995Minimed Inc.Transcutaneous sensor insertion set
US5391250 *15 mars 199421 févr. 1995Minimed Inc.Method of fabricating thin film sensors
US5494562 *27 juin 199427 févr. 1996Ciba Corning Diagnostics Corp.Electrochemical sensors
US5593852 *1 sept. 199414 janv. 1997Heller; AdamSubcutaneous glucose electrode
US5596150 *8 mars 199521 janv. 1997The United States Of America As Represented By The Administrator Of The National Aeronautics And Space AdministrationCapacitance probe for fluid flow and volume measurements
US5708247 *14 févr. 199613 janv. 1998Selfcare, Inc.Disposable glucose test strips, and methods and compositions for making same
US5711001 *29 mai 199620 janv. 1998Motorola, Inc.Method and circuit for acquisition by a radio receiver
US5711861 *22 nov. 199527 janv. 1998Ward; W. KennethDevice for monitoring changes in analyte concentration
US5711862 *15 mars 199627 janv. 1998Omron CorporationPortable biochemical measurement device using an enzyme sensor
US6020110 *23 juin 19951 févr. 2000Cambridge Sensors Ltd.Production of electrodes for electrochemical sensing
US6024699 *13 mars 199815 févr. 2000Healthware CorporationSystems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6175752 *30 avr. 199816 janv. 2001Therasense, Inc.Analyte monitoring device and methods of use
US6514718 *29 nov. 20014 févr. 2003Therasense, Inc.Subcutaneous glucose electrode
US6689056 *6 avr. 200010 févr. 2004Medtronic Endonetics, Inc.Implantable monitoring probe
US6990366 *24 nov. 200324 janv. 2006Therasense, Inc.Analyte monitoring device and methods of use
US7003340 *11 nov. 200221 févr. 2006Abbott Diabetes Care Inc.Electrochemical analyte sensor
US7003341 *24 nov. 200321 févr. 2006Abbott Diabetes Care, Inc.Analyte monitoring devices and methods of use
US7651596 *18 janv. 200626 janv. 2010Dexcom, Inc.Cellulosic-based interference domain for an analyte sensor
US20030023317 *27 juil. 200130 janv. 2003Dexcom, Inc.Membrane for use with implantable devices
US20030032874 *27 juil. 200113 févr. 2003Dexcom, Inc.Sensor head for use with implantable devices
US20040011671 *27 juil. 200122 janv. 2004Dexcom, Inc.Device and method for determining analyte levels
US20050031689 *10 mai 200410 févr. 2005Dexcom, Inc.Biointerface membranes incorporating bioactive agents
US20050043598 *22 août 200324 févr. 2005Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20060003398 *15 juil. 20055 janv. 2006Therasense, Inc.Subcutaneous glucose electrode
US20060015020 *6 juil. 200419 janv. 2006Dexcom, Inc.Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20060016700 *21 juin 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060019327 *10 mars 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020186 *10 mars 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020188 *10 mars 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020189 *10 mars 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020190 *10 mars 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020191 *10 mars 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020192 *10 mars 200526 janv. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036139 *10 mars 200516 févr. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036140 *10 mars 200516 févr. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036141 *10 mars 200516 févr. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036142 *10 mars 200516 févr. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036144 *21 juin 200516 févr. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036145 *21 juin 200516 févr. 2006Dexcom, Inc.Transcutaneous analyte sensor
US20070016381 *1 sept. 200618 janv. 2007Apurv KamathSystems and methods for processing analyte sensor data
US20070042377 *25 oct. 200422 févr. 2007Zhiqiang GaoBiosensor
US20080021666 *1 oct. 200724 janv. 2008Dexcom, Inc.System and methods for processing analyte sensor data
US20080033254 *13 juin 20077 févr. 2008Dexcom, Inc.Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US20090012379 *20 août 20088 janv. 2009Dexcom, Inc.System and methods for processing analyte sensor data
US20090018424 *25 mars 200815 janv. 2009Dexcom, Inc.Analyte sensor
US20090030294 *7 oct. 200829 janv. 2009Dexcom, Inc.Implantable analyte sensor
US20090036758 *16 oct. 20085 févr. 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090036763 *14 oct. 20085 févr. 2009Dexcom, Inc.Analyte sensor
US20090043181 *16 oct. 200812 févr. 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090043182 *16 oct. 200812 févr. 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090043525 *16 oct. 200812 févr. 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090043541 *16 oct. 200812 févr. 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090043542 *16 oct. 200812 févr. 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090045055 *28 oct. 200819 févr. 2009Dexcom, Inc.Sensor head for use with implantable devices
US20100010324 *23 sept. 200914 janv. 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100010331 *23 sept. 200914 janv. 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100010332 *23 sept. 200914 janv. 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100016687 *23 sept. 200921 janv. 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100016698 *23 sept. 200921 janv. 2010Dexcom, Inc.Integrated receiver for continuous analyte sensor
US20100022855 *23 sept. 200928 janv. 2010Dexcom, Inc.Signal processing for continuous analyte sensor
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US764846831 déc. 200219 janv. 2010Pelikon Technologies, Inc.Method and apparatus for penetrating tissue
US76534259 août 200626 janv. 2010Abbott Diabetes Care Inc.Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US766614928 oct. 200223 févr. 2010Peliken Technologies, Inc.Cassette of lancet cartridges for sampling blood
US767423231 déc. 20029 mars 2010Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US767940727 avr. 200416 mars 2010Abbott Diabetes Care Inc.Method and apparatus for providing peak detection circuitry for data communication systems
US768231812 juin 200223 mars 2010Pelikan Technologies, Inc.Blood sampling apparatus and method
US769796728 sept. 200613 avr. 2010Abbott Diabetes Care Inc.Method and apparatus for providing analyte sensor insertion
US769979112 juin 200220 avr. 2010Pelikan Technologies, Inc.Method and apparatus for improving success rate of blood yield from a fingerstick
US771321418 déc. 200211 mai 2010Pelikan Technologies, Inc.Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US771786331 déc. 200218 mai 2010Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US773172913 févr. 20078 juin 2010Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US773631030 janv. 200615 juin 2010Abbott Diabetes Care Inc.On-body medical device securement
US775656130 sept. 200513 juil. 2010Abbott Diabetes Care Inc.Method and apparatus for providing rechargeable power in data monitoring and management systems
US77668294 nov. 20053 août 2010Abbott Diabetes Care Inc.Method and system for providing basal profile modification in analyte monitoring and management systems
US776838631 juil. 20073 août 2010Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US776838714 avr. 20083 août 2010Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US776840817 mai 20063 août 2010Abbott Diabetes Care Inc.Method and system for providing data management in data monitoring system
US780158231 mars 200621 sept. 2010Abbott Diabetes Care Inc.Analyte monitoring and management system and methods therefor
US781123126 déc. 200312 oct. 2010Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US78224543 janv. 200526 oct. 2010Pelikan Technologies, Inc.Fluid sampling device with improved analyte detecting member configuration
US782245531 juil. 200926 oct. 2010Abbott Diabetes Care Inc.Analyte sensors and methods of use
US782638230 mai 20082 nov. 2010Abbott Diabetes Care Inc.Close proximity communication device and methods
US782687928 févr. 20062 nov. 2010Abbott Diabetes Care Inc.Analyte sensors and methods of use
US783317113 févr. 200716 nov. 2010Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US784199222 déc. 200530 nov. 2010Pelikan Technologies, Inc.Tissue penetration device
US78506217 juin 200414 déc. 2010Pelikan Technologies, Inc.Method and apparatus for body fluid sampling and analyte sensing
US785062222 déc. 200514 déc. 2010Pelikan Technologies, Inc.Tissue penetration device
US78605447 mars 200728 déc. 2010Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US786252020 juin 20084 janv. 2011Pelikan Technologies, Inc.Body fluid sampling module with a continuous compression tissue interface surface
US78698536 août 201011 janv. 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US787499416 oct. 200625 janv. 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US788346430 sept. 20058 févr. 2011Abbott Diabetes Care Inc.Integrated transmitter unit and sensor introducer mechanism and methods of use
US78847292 août 20108 févr. 2011Abbott Diabetes Care Inc.Method and system for providing data management in data monitoring system
US788569828 févr. 20068 févr. 2011Abbott Diabetes Care Inc.Method and system for providing continuous calibration of implantable analyte sensors
US78856996 août 20108 févr. 2011Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US78921833 juil. 200322 févr. 2011Pelikan Technologies, Inc.Method and apparatus for body fluid sampling and analyte sensing
US790136231 déc. 20028 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US790977413 févr. 200722 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US790977526 juin 200722 mars 2011Pelikan Technologies, Inc.Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US790977729 sept. 200622 mars 2011Pelikan Technologies, IncMethod and apparatus for penetrating tissue
US790977820 avr. 200722 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US79144658 févr. 200729 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US79209077 juin 20075 avr. 2011Abbott Diabetes Care Inc.Analyte monitoring system and method
US792245829 déc. 200812 avr. 2011Abbott Diabetes Care Inc.Variable volume, shape memory actuated insulin dispensing pump
US79288508 mai 200819 avr. 2011Abbott Diabetes Care Inc.Analyte monitoring system and methods
US793878729 sept. 200610 mai 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US79483692 août 201024 mai 2011Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US795108030 oct. 200931 mai 2011Abbott Diabetes Care Inc.On-body medical device securement
US795958221 mars 200714 juin 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US797647616 mars 200712 juil. 2011Pelikan Technologies, Inc.Device and method for variable speed lancet
US797677822 juin 200512 juil. 2011Abbott Diabetes Care Inc.Blood glucose tracking apparatus
US798105522 déc. 200519 juil. 2011Pelikan Technologies, Inc.Tissue penetration device
US798105618 juin 200719 juil. 2011Pelikan Technologies, Inc.Methods and apparatus for lancet actuation
US798864421 mars 20072 août 2011Pelikan Technologies, Inc.Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US79886453 mai 20072 août 2011Pelikan Technologies, Inc.Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US799310813 avr. 20059 août 2011Abbott Diabetes Care Inc.Variable volume, shape memory actuated insulin dispensing pump
US799310929 déc. 20089 août 2011Abbott Diabetes Care Inc.Variable volume, shape memory actuated insulin dispensing pump
US799605420 févr. 20069 août 2011Abbott Diabetes Care Inc.Electrochemical analyte sensor
US799615814 mai 20089 août 2011Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US800744619 oct. 200630 août 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US801677422 déc. 200513 sept. 2011Pelikan Technologies, Inc.Tissue penetration device
US802924529 déc. 20084 oct. 2011Abbott Diabetes Care Inc.Variable volume, shape memory actuated insulin dispensing pump
US802925029 déc. 20084 oct. 2011Abbott Diabetes Care Inc.Variable volume, shape memory actuated insulin dispensing pump
US802944128 févr. 20064 oct. 2011Abbott Diabetes Care Inc.Analyte sensor transmitter unit configuration for a data monitoring and management system
US802945921 déc. 20094 oct. 2011Abbott Diabetes Care Inc.Method and system for providing integrated medication infusion and analyte monitoring system
US802946021 déc. 20094 oct. 2011Abbott Diabetes Care Inc.Method and system for providing integrated medication infusion and analyte monitoring system
US804781129 déc. 20081 nov. 2011Abbott Diabetes Care Inc.Variable volume, shape memory actuated insulin dispensing pump
US804781229 déc. 20081 nov. 2011Abbott Diabetes Care Inc.Variable volume, shape memory actuated insulin dispensing pump
US806223111 oct. 200622 nov. 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US80666394 juin 200429 nov. 2011Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US807996010 oct. 200620 déc. 2011Pelikan Technologies, Inc.Methods and apparatus for lancet actuation
US808629227 oct. 200927 déc. 2011Abbott Diabetes Care Inc.Analyte monitoring and management system and methods therefor
US80893637 févr. 20113 janv. 2012Abbott Diabetes Care Inc.Method and system for providing data management in data monitoring system
US810345629 janv. 200924 janv. 2012Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US810347114 mai 200824 janv. 2012Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US811213826 sept. 20087 févr. 2012Abbott Diabetes Care Inc.Method and apparatus for providing rechargeable power in data monitoring and management systems
US811224029 avr. 20057 févr. 2012Abbott Diabetes Care Inc.Method and apparatus for providing leak detection in data monitoring and management systems
US811684030 oct. 200714 févr. 2012Abbott Diabetes Care Inc.Method of calibrating of an analyte-measurement device, and associated methods, devices and systems
US81236861 mars 200728 févr. 2012Abbott Diabetes Care Inc.Method and apparatus for providing rolling data in communication systems
US812370026 juin 200728 févr. 2012Pelikan Technologies, Inc.Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US813554826 oct. 200713 mars 2012Abbott Diabetes Care Inc.Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US814014214 avr. 200820 mars 2012Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in medical communication system
US814031231 janv. 200820 mars 2012Abbott Diabetes Care Inc.Method and system for determining analyte levels
US814910323 mai 20113 avr. 2012Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage amplification in a medical device
US814911729 août 20093 avr. 2012Abbott Diabetes Care Inc.Analyte monitoring system and methods
US81606703 juil. 200817 avr. 2012Abbott Diabetes Care Inc.Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent
US816090026 juin 200817 avr. 2012Abbott Diabetes Care Inc.Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US816282930 mars 200924 avr. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US816285322 déc. 200524 avr. 2012Pelikan Technologies, Inc.Tissue penetration device
US81756739 nov. 20098 mai 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US817771621 déc. 200915 mai 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US818518129 oct. 201022 mai 2012Abbott Diabetes Care Inc.Method and apparatus for detecting false hypoglycemic conditions
US818718311 oct. 201029 mai 2012Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US819742116 juil. 200712 juin 2012Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US819742314 déc. 201012 juin 2012Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US820223123 avr. 200719 juin 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US820631722 déc. 200526 juin 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US820631926 août 201026 juin 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US821101626 sept. 20083 juil. 2012Abbott Diabetes Care Inc.Method and system for providing analyte monitoring
US821103722 déc. 20053 juil. 2012Pelikan Technologies, Inc.Tissue penetration device
US821613720 juil. 200910 juil. 2012Abbott Diabetes Care Inc.Method and system for providing analyte monitoring
US821613823 oct. 200810 juil. 2012Abbott Diabetes Care Inc.Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US821615423 déc. 200510 juil. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US821917330 sept. 200810 juil. 2012Abbott Diabetes Care Inc.Optimizing analyte sensor calibration
US821917429 juin 200910 juil. 2012Abbott Diabetes Care Inc.Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US821917529 juin 200910 juil. 2012Abbott Diabetes Care Inc.Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US822133422 déc. 201017 juil. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US822441310 oct. 200817 juil. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822441529 janv. 200917 juil. 2012Abbott Diabetes Care Inc.Method and device for providing offset model based calibration for analyte sensor
US822655518 mars 200924 juil. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822655728 déc. 200924 juil. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822655827 sept. 201024 juil. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US822689131 mars 200624 juil. 2012Abbott Diabetes Care Inc.Analyte monitoring devices and methods therefor
US823153230 avr. 200731 juil. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US823589621 déc. 20097 août 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US823624212 févr. 20107 août 2012Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US823916614 mai 20087 août 2012Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US825192110 juin 201028 août 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for body fluid sampling and analyte sensing
US825222910 avr. 200928 août 2012Abbott Diabetes Care Inc.Method and system for sterilizing an analyte sensor
US825503117 mars 200928 août 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US82603929 juin 20084 sept. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US826055814 mai 20084 sept. 2012Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US82657269 nov. 200911 sept. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US826787030 mai 200318 sept. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for body fluid sampling with hybrid actuation
US826824328 déc. 200918 sept. 2012Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US827302213 févr. 200925 sept. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US82754399 nov. 200925 sept. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US828257629 sept. 20049 oct. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for an improved sample capture device
US828257715 juin 20079 oct. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US828745427 sept. 201016 oct. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US829691823 août 201030 oct. 2012Sanofi-Aventis Deutschland GmbhMethod of manufacturing a fluid sampling device with improved analyte detecting member configuration
US83065989 nov. 20096 nov. 2012Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US83337105 oct. 200518 déc. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US833371410 sept. 200618 déc. 2012Abbott Diabetes Care Inc.Method and system for providing an integrated analyte sensor insertion device and data processing unit
US83374194 oct. 200525 déc. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US833742024 mars 200625 déc. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US834307523 déc. 20051 janv. 2013Sanofi-Aventis Deutschland GmbhTissue penetration device
US834309224 nov. 20091 janv. 2013Abbott Diabetes Care Inc.Method and system for providing integrated medication infusion and analyte monitoring system
US834309328 mai 20101 janv. 2013Abbott Diabetes Care Inc.Fluid delivery device with autocalibration
US834496631 janv. 20061 janv. 2013Abbott Diabetes Care Inc.Method and system for providing a fault tolerant display unit in an electronic device
US834633530 janv. 20091 janv. 2013Abbott Diabetes Care Inc.Analyte sensor calibration management
US834633618 mars 20091 janv. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US834633730 juin 20091 janv. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US835382921 déc. 200915 janv. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US835709121 déc. 200922 janv. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US836099123 déc. 200529 janv. 2013Sanofi-Aventis Deutschland GmbhTissue penetration device
US836290418 avr. 201129 janv. 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US836661430 mars 20095 févr. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US836855629 avr. 20105 févr. 2013Abbott Diabetes Care Inc.Method and system for providing data communication in continuous glucose monitoring and management system
US837200521 déc. 200912 févr. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US837466823 oct. 200812 févr. 2013Abbott Diabetes Care Inc.Analyte sensor with lag compensation
US837694523 nov. 200919 févr. 2013Abbott Diabetes Care Inc.Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US837703131 août 200819 févr. 2013Abbott Diabetes Care Inc.Closed loop control system with safety parameters and methods
US838027311 avr. 200919 févr. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US83826826 févr. 200726 févr. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US83826837 mars 201226 févr. 2013Sanofi-Aventis Deutschland GmbhTissue penetration device
US838855127 mai 20085 mars 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for multi-use body fluid sampling device with sterility barrier release
US839194517 mars 20095 mars 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US84038641 mai 200626 mars 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US840909323 oct. 20082 avr. 2013Abbott Diabetes Care Inc.Assessing measures of glycemic variability
US84091317 mars 20072 avr. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US841450316 mars 20079 avr. 2013Sanofi-Aventis Deutschland GmbhMethods and apparatus for lancet actuation
US841475029 sept. 20109 avr. 2013Abbott Diabetes Care Inc.Subcutaneous glucose electrode
US841754517 févr. 20129 avr. 2013Abbott Diabetes Care Inc.Device and method for automatic data acquisition and/or detection
US84272982 avr. 201223 avr. 2013Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage amplification in a medical device
US843082826 janv. 200730 avr. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for a multi-use body fluid sampling device with sterility barrier release
US843519019 janv. 20077 mai 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US843987226 avr. 201014 mai 2013Sanofi-Aventis Deutschland GmbhApparatus and method for penetration with shaft having a sensor for sensing penetration depth
US844456014 mai 200821 mai 2013Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US84563018 mai 20084 juin 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US84619858 mai 200811 juin 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US84633516 août 201011 juin 2013Abbott Diabetes Care Inc.Electrochemical analyte sensor
US846542530 juin 200918 juin 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US846797228 avr. 201018 juin 2013Abbott Diabetes Care Inc.Closed loop blood glucose control algorithm analysis
US847171430 déc. 201125 juin 2013Abbott Diabetes Care Inc.Method and system for providing data management in data monitoring system
US847302131 juil. 200925 juin 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US847302230 janv. 200925 juin 2013Abbott Diabetes Care Inc.Analyte sensor with time lag compensation
US847322023 janv. 201225 juin 2013Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US847855730 juil. 20102 juil. 2013Abbott Diabetes Care Inc.Method and apparatus for providing analyte monitoring system calibration accuracy
US848058019 avr. 20079 juil. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US848396728 avr. 20109 juil. 2013Abbott Diabetes Care Inc.Method and system for providing real time analyte sensor calibration with retrospective backfill
US848400519 mars 20129 juil. 2013Abbott Diabetes Care Inc.Method and system for determining analyte levels
US849777715 avr. 201030 juil. 2013Abbott Diabetes Care Inc.Analyte monitoring system having an alert
US85064827 févr. 201113 août 2013Abbott Diabetes Care Inc.Method and system for providing continuous calibration of implantable analyte sensors
US85091071 nov. 201013 août 2013Abbott Diabetes Care Inc.Close proximity communication device and methods
US851223920 avr. 200920 août 2013Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US851224330 sept. 200520 août 2013Abbott Diabetes Care Inc.Integrated introducer and transmitter assembly and methods of use
US851224615 mars 201020 août 2013Abbott Diabetes Care Inc.Method and apparatus for providing peak detection circuitry for data communication systems
US851408630 août 201020 août 2013Abbott Diabetes Care Inc.Displays for a medical device
US851551730 sept. 200920 août 2013Abbott Diabetes Care Inc.Method and system for dynamically updating calibration parameters for an analyte sensor
US851551828 déc. 200520 août 2013Abbott Diabetes Care Inc.Analyte monitoring
US853293516 juil. 201210 sept. 2013Abbott Diabetes Care Inc.Method and device for providing offset model based calibration for analyte sensor
US854318323 déc. 201124 sept. 2013Abbott Diabetes Care Inc.Analyte monitoring and management system and methods therefor
US854540328 déc. 20061 oct. 2013Abbott Diabetes Care Inc.Medical device insertion
US856003814 mai 200815 oct. 2013Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US856008230 janv. 200915 oct. 2013Abbott Diabetes Care Inc.Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
US857162429 déc. 200429 oct. 2013Abbott Diabetes Care Inc.Method and apparatus for mounting a data transmission device in a communication system
US857180823 janv. 201229 oct. 2013Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US85798316 oct. 200612 nov. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US857985331 oct. 200612 nov. 2013Abbott Diabetes Care Inc.Infusion devices and methods
US858320516 avr. 201012 nov. 2013Abbott Diabetes Care Inc.Analyte sensor calibration management
US858559110 juil. 201019 nov. 2013Abbott Diabetes Care Inc.Method and system for providing basal profile modification in analyte monitoring and management systems
US85888812 mars 200719 nov. 2013Abbott Diabetes Care Inc.Subcutaneous glucose electrode
US85914101 juin 200926 nov. 2013Abbott Diabetes Care Inc.Method and apparatus for providing glycemic control
US85931093 nov. 200926 nov. 2013Abbott Diabetes Care Inc.Method and system for powering an electronic device
US859328720 juil. 201226 nov. 2013Abbott Diabetes Care Inc.Analyte monitoring system and methods
US859718820 juin 20083 déc. 2013Abbott Diabetes Care Inc.Health management devices and methods
US85971893 mars 20093 déc. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US859757523 juil. 20123 déc. 2013Abbott Diabetes Care Inc.Analyte monitoring devices and methods therefor
US860068114 mai 20083 déc. 2013Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US86029917 juin 201010 déc. 2013Abbott Diabetes Care Inc.Analyte sensor introducer and methods of use
US861215916 févr. 200417 déc. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US861216330 août 201217 déc. 2013Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US861370329 mai 200824 déc. 2013Abbott Diabetes Care Inc.Insertion devices and methods
US861389230 juin 200924 déc. 2013Abbott Diabetes Care Inc.Analyte meter with a moveable head and methods of using the same
US861706920 juin 200831 déc. 2013Abbott Diabetes Care Inc.Health monitor
US861707121 juin 200731 déc. 2013Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US862290325 mai 20127 janv. 2014Abbott Diabetes Care Inc.Continuous glucose monitoring system and methods of use
US862290621 déc. 20097 janv. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US862293018 juil. 20117 janv. 2014Sanofi-Aventis Deutschland GmbhTissue penetration device
US862298831 août 20087 janv. 2014Abbott Diabetes Care Inc.Variable rate closed loop control and methods
US863504622 juin 201121 janv. 2014Abbott Diabetes Care Inc.Method and system for evaluating analyte sensor response characteristics
US863822023 mai 201128 janv. 2014Abbott Diabetes Care Inc.Method and apparatus for providing data communication in data monitoring and management systems
US864161921 déc. 20094 févr. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US864164327 avr. 20064 févr. 2014Sanofi-Aventis Deutschland GmbhSampling module device and method
US864726920 avr. 200911 févr. 2014Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US86498413 avr. 200711 févr. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US865204320 juil. 201218 févr. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US865283126 mars 200818 févr. 2014Sanofi-Aventis Deutschland GmbhMethod and apparatus for analyte measurement test time
US865397721 juin 201318 févr. 2014Abbott Diabetes Care Inc.Method and system for providing data management in data monitoring system
US866062717 mars 200925 févr. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US866509130 juin 20094 mars 2014Abbott Diabetes Care Inc.Method and device for determining elapsed sensor life
US866646916 nov. 20074 mars 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US86686453 janv. 200311 mars 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US866865631 déc. 200411 mars 2014Sanofi-Aventis Deutschland GmbhMethod and apparatus for improving fluidic flow and sample capture
US867081530 avr. 200711 mars 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US867284427 févr. 200418 mars 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US867651321 juin 201318 mars 2014Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US86766018 avr. 201318 mars 2014Abbott Diabetes Care Inc.Device and method for automatic data acquisition and/or detection
US867903316 juin 201125 mars 2014Sanofi-Aventis Deutschland GmbhTissue penetration device
US86826154 août 201225 mars 2014Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US868493029 juin 20091 avr. 2014Abbott Diabetes Care Inc.Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US868818830 juin 20091 avr. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US869079629 sept. 20068 avr. 2014Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US869861522 avr. 201315 avr. 2014Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US870262429 janv. 201022 avr. 2014Sanofi-Aventis Deutschland GmbhAnalyte measurement device with a single shot actuator
US870618010 juin 201322 avr. 2014Abbott Diabetes Care Inc.Electrochemical analyte sensor
US871099321 nov. 201229 avr. 2014Abbott Diabetes Care Inc.Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US871873928 déc. 20126 mai 2014Abbott Diabetes Care Inc.Analyte sensor calibration management
US871895812 mars 20126 mai 2014Abbott Diabetes Care Inc.Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US871896524 juin 20136 mai 2014Abbott Diabetes Care Inc.Method and apparatus for providing analyte monitoring system calibration accuracy
US87216716 juil. 200513 mai 2014Sanofi-Aventis Deutschland GmbhElectric lancet actuator
US873005829 juil. 201320 mai 2014Abbott Diabetes Care Inc.Analyte monitoring system having an alert
US873218815 févr. 200820 mai 2014Abbott Diabetes Care Inc.Method and system for providing contextual based medication dosage determination
US873434429 mai 201127 mai 2014Abbott Diabetes Care Inc.On-body medical device securement
US873434630 avr. 200727 mai 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US873434817 mars 200927 mai 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US873442231 août 200827 mai 2014Abbott Diabetes Care Inc.Closed loop control with improved alarm functions
US87372595 août 201327 mai 2014Abbott Diabetes Care Inc.Close proximity communication device and methods
US87381093 mars 200927 mai 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US87415903 avr. 20073 juin 2014Abbott Diabetes Care Inc.Subcutaneous glucose electrode
US87445453 mars 20093 juin 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US87445479 juil. 20123 juin 2014Abbott Diabetes Care Inc.Optimizing analyte sensor calibration
US876465730 mars 20121 juil. 2014Abbott Diabetes Care Inc.Medical device inserters and processes of inserting and using medical devices
US876505927 oct. 20101 juil. 2014Abbott Diabetes Care Inc.Blood glucose tracking apparatus
US877118316 févr. 20058 juil. 2014Abbott Diabetes Care Inc.Method and system for providing data communication in continuous glucose monitoring and management system
US877488724 mars 20078 juil. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US87929562 avr. 201229 juil. 2014Abbott Diabetes Care Inc.Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent
US879525216 oct. 20095 août 2014Abbott Diabetes Care Inc.Robust closed loop control and methods
US879893423 juil. 20105 août 2014Abbott Diabetes Care Inc.Real time management of data relating to physiological control of glucose levels
US880200627 août 201212 août 2014Abbott Diabetes Care Inc.Method and system for sterilizing an analyte sensor
US881686219 août 201326 août 2014Abbott Diabetes Care Inc.Displays for a medical device
US882820320 mai 20059 sept. 2014Sanofi-Aventis Deutschland GmbhPrintable hydrogels for biosensors
US883436631 juil. 200716 sept. 2014Abbott Diabetes Care Inc.Method and apparatus for providing analyte sensor calibration
US884055326 févr. 200923 sept. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US88455503 déc. 201230 sept. 2014Sanofi-Aventis Deutschland GmbhTissue penetration device
US885210130 sept. 20097 oct. 2014Abbott Diabetes Care Inc.Method and apparatus for providing analyte sensor insertion
US886219817 déc. 201214 oct. 2014Abbott Diabetes Care Inc.Method and system for providing an integrated analyte sensor insertion device and data processing unit
US887675514 juil. 20094 nov. 2014Abbott Diabetes Care Inc.Closed loop control system interface and methods
US888013718 avr. 20034 nov. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US888013830 sept. 20054 nov. 2014Abbott Diabetes Care Inc.Device for channeling fluid and methods of use
US890594529 mars 20129 déc. 2014Dominique M. FreemanMethod and apparatus for penetrating tissue
US891585028 mars 201423 déc. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US892031928 déc. 201230 déc. 2014Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US89241591 juin 200930 déc. 2014Abbott Diabetes Care Inc.Method and apparatus for providing glycemic control
US89302033 févr. 20106 janv. 2015Abbott Diabetes Care Inc.Multi-function analyte test device and methods therefor
US893366425 nov. 201313 janv. 2015Abbott Diabetes Care Inc.Method and system for powering an electronic device
US893754024 févr. 201420 janv. 2015Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US894591019 juin 20123 févr. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for an improved sample capture device
US896547618 avr. 201124 févr. 2015Sanofi-Aventis Deutschland GmbhTissue penetration device
US89743861 nov. 200510 mars 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US898620830 sept. 200824 mars 2015Abbott Diabetes Care Inc.Analyte sensor sensitivity attenuation mitigation
US899333131 août 201031 mars 2015Abbott Diabetes Care Inc.Analyte monitoring system and methods for managing power and noise
US900092922 nov. 20137 avr. 2015Abbott Diabetes Care Inc.Analyte monitoring system and methods
US900874314 avr. 200814 avr. 2015Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in medical communication system
US901133129 déc. 200421 avr. 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US901133230 oct. 200721 avr. 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US90147737 mars 200721 avr. 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US90316301 nov. 201012 mai 2015Abbott Diabetes Care Inc.Analyte sensors and methods of use
US903463926 juin 201219 mai 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus using optical techniques to measure analyte levels
US903576730 mai 201319 mai 2015Abbott Diabetes Care Inc.Analyte monitoring system and methods
US90399752 déc. 201326 mai 2015Abbott Diabetes Care Inc.Analyte monitoring devices and methods therefor
US90429532 mars 200726 mai 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US905004121 mai 20129 juin 2015Abbott Diabetes Care Inc.Method and apparatus for detecting false hypoglycemic conditions
US906071913 déc. 201323 juin 2015Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US906410730 sept. 201323 juin 2015Abbott Diabetes Care Inc.Infusion devices and methods
US90666943 avr. 200730 juin 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US906669512 avr. 200730 juin 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US906669727 oct. 201130 juin 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US906670917 mars 201430 juin 2015Abbott Diabetes Care Inc.Method and device for early signal attenuation detection using blood glucose measurements
US906953630 oct. 201230 juin 2015Abbott Diabetes Care Inc.Electronic devices having integrated reset systems and methods thereof
US907247721 juin 20077 juil. 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US907284231 juil. 20137 juil. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US907860717 juin 201314 juil. 2015Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US908845231 janv. 201321 juil. 2015Abbott Diabetes Care Inc.Method and system for providing data communication in continuous glucose monitoring and management system
US908929416 janv. 201428 juil. 2015Sanofi-Aventis Deutschland GmbhAnalyte measurement device with a single shot actuator
US908967821 mai 201228 juil. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US909529027 févr. 20124 août 2015Abbott Diabetes Care Inc.Method and apparatus for providing rolling data in communication systems
US91138289 juil. 201225 août 2015Abbott Diabetes Care Inc.Method and system for providing analyte monitoring
US912554814 mai 20088 sept. 2015Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US914440112 déc. 200529 sept. 2015Sanofi-Aventis Deutschland GmbhLow pain penetrating member
US917745610 juin 20133 nov. 2015Abbott Diabetes Care Inc.Analyte monitoring system and methods
US917875225 avr. 20143 nov. 2015Abbott Diabetes Care Inc.Analyte monitoring system having an alert
US918487525 avr. 201410 nov. 2015Abbott Diabetes Care, Inc.Close proximity communication device and methods
US918609824 mars 201117 nov. 2015Abbott Diabetes Care Inc.Medical device inserters and processes of inserting and using medical devices
US918611311 août 201417 nov. 2015Abbott Diabetes Care Inc.Displays for a medical device
US918646814 janv. 201417 nov. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US920482714 avr. 20088 déc. 2015Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in medical communication system
US921599224 mars 201122 déc. 2015Abbott Diabetes Care Inc.Medical device inserters and processes of inserting and using medical devices
US92266999 nov. 20105 janv. 2016Sanofi-Aventis Deutschland GmbhBody fluid sampling module with a continuous compression tissue interface surface
US922670128 avr. 20105 janv. 2016Abbott Diabetes Care Inc.Error detection in critical repeating data in a wireless sensor system
US92267148 janv. 20155 janv. 2016Abbott Diabetes Care Inc.Displays for a medical device
US924826718 juil. 20132 févr. 2016Sanofi-Aventis Deustchland GmbhTissue penetration device
US925917523 oct. 200616 févr. 2016Abbott Diabetes Care, Inc.Flexible patch for fluid delivery and monitoring body analytes
US92614761 avr. 201416 févr. 2016Sanofi SaPrintable hydrogel for biosensors
US926545324 mars 201123 févr. 2016Abbott Diabetes Care Inc.Medical device inserters and processes of inserting and using medical devices
US928917911 avr. 201422 mars 2016Abbott Diabetes Care Inc.Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US931023024 juin 201312 avr. 2016Abbott Diabetes Care Inc.Method and system for providing real time analyte sensor calibration with retrospective backfill
US931419411 janv. 200719 avr. 2016Sanofi-Aventis Deutschland GmbhTissue penetration device
US931419531 août 201019 avr. 2016Abbott Diabetes Care Inc.Analyte signal processing device and methods
US93141983 avr. 201519 avr. 2016Abbott Diabetes Care Inc.Analyte monitoring system and methods
US931765621 nov. 201219 avr. 2016Abbott Diabetes Care Inc.Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US932046129 sept. 201026 avr. 2016Abbott Diabetes Care Inc.Method and apparatus for providing notification function in analyte monitoring systems
US93204625 mai 201426 avr. 2016Abbott Diabetes Care Inc.Analyte sensor calibration management
US932046821 juin 201326 avr. 2016Abbott Diabetes Care Inc.Analyte sensor with time lag compensation
US932389815 nov. 201326 avr. 2016Abbott Diabetes Care Inc.Method and system for providing basal profile modification in analyte monitoring and management systems
US932670710 nov. 20093 mai 2016Abbott Diabetes Care Inc.Alarm characterization for analyte monitoring devices and systems
US93267099 mars 20113 mai 2016Abbott Diabetes Care Inc.Systems, devices and methods for managing glucose levels
US932671429 juin 20103 mai 2016Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US93267165 déc. 20143 mai 2016Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US932672715 mai 20143 mai 2016Abbott Diabetes Care Inc.On-body medical device securement
US933293329 sept. 201410 mai 2016Abbott Diabetes Care Inc.Method and apparatus for providing analyte sensor insertion
US93329348 févr. 201310 mai 2016Abbott Diabetes Care Inc.Analyte sensor with lag compensation
US933294431 janv. 201410 mai 2016Abbott Diabetes Care Inc.Method and system for providing data management in data monitoring system
US933921721 nov. 201217 mai 2016Abbott Diabetes Care Inc.Analyte monitoring system and methods of use
US935166930 sept. 201031 mai 2016Abbott Diabetes Care Inc.Interconnect for on-body analyte monitoring device
US935168014 oct. 200431 mai 2016Sanofi-Aventis Deutschland GmbhMethod and apparatus for a variable user interface
US935795919 août 20137 juin 2016Abbott Diabetes Care Inc.Method and system for dynamically updating calibration parameters for an analyte sensor
US93641493 oct. 201114 juin 2016Abbott Diabetes Care Inc.Analyte sensor transmitter unit configuration for a data monitoring and management system
US937516929 janv. 201028 juin 2016Sanofi-Aventis Deutschland GmbhCam drive for managing disposable penetrating member actions with a single motor and motor and control system
US93809715 déc. 20145 juil. 2016Abbott Diabetes Care Inc.Method and system for powering an electronic device
US938694410 avr. 200912 juil. 2016Sanofi-Aventis Deutschland GmbhMethod and apparatus for analyte detecting device
US939296931 août 200819 juil. 2016Abbott Diabetes Care Inc.Closed loop control and signal attenuation detection
US939887228 août 201426 juil. 2016Abbott Diabetes Care Inc.Method and apparatus for providing analyte sensor calibration
US939888210 sept. 200626 juil. 2016Abbott Diabetes Care Inc.Method and apparatus for providing analyte sensor and data processing device
US94025441 févr. 20102 août 2016Abbott Diabetes Care Inc.Analyte sensor and apparatus for insertion of the sensor
US940257011 déc. 20122 août 2016Abbott Diabetes Care Inc.Analyte sensor devices, connections, and methods
US940258414 janv. 20152 août 2016Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US940856613 févr. 20139 août 2016Abbott Diabetes Care Inc.Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US942753229 sept. 201430 août 2016Sanofi-Aventis Deutschland GmbhTissue penetration device
US943958629 mars 201313 sept. 2016Abbott Diabetes Care Inc.Assessing measures of glycemic variability
US946542026 juin 201511 oct. 2016Abbott Diabetes Care Inc.Electronic devices having integrated reset systems and methods thereof
US947447513 mars 201425 oct. 2016Abbott Diabetes Care Inc.Multi-rate analyte sensor data collection with sample rate configurable signal processing
US947781123 juin 200525 oct. 2016Abbott Diabetes Care Inc.Blood glucose tracking apparatus and methods
US948042119 août 20131 nov. 2016Abbott Diabetes Care Inc.Integrated introducer and transmitter assembly and methods of use
US948360820 mai 20131 nov. 2016Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US949815930 oct. 200722 nov. 2016Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US949816029 sept. 201422 nov. 2016Sanofi-Aventis Deutschland GmbhMethod for penetrating tissue
US952196830 sept. 200520 déc. 2016Abbott Diabetes Care Inc.Analyte sensor retention mechanism and methods of use
US953273728 févr. 20123 janv. 2017Abbott Diabetes Care Inc.Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US954155625 nov. 201310 janv. 2017Abbott Diabetes Care Inc.Method and apparatus for providing glycemic control
US954969411 nov. 201524 janv. 2017Abbott Diabetes Care Inc.Displays for a medical device
US955832524 juin 201331 janv. 2017Abbott Diabetes Care Inc.Method and system for determining analyte levels
US956099320 déc. 20137 févr. 2017Sanofi-Aventis Deutschland GmbhBlood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US956100010 déc. 20137 févr. 2017Sanofi-Aventis Deutschland GmbhMethod and apparatus for improving fluidic flow and sample capture
US957253428 juin 201121 févr. 2017Abbott Diabetes Care Inc.Devices, systems and methods for on-skin or on-body mounting of medical devices
US95729341 août 201421 févr. 2017Abbott DiabetesCare Inc.Robust closed loop control and methods
US95749143 mars 201421 févr. 2017Abbott Diabetes Care Inc.Method and device for determining elapsed sensor life
US96100349 nov. 20154 avr. 2017Abbott Diabetes Care Inc.Analyte monitoring device and methods of use
US961004629 avr. 20144 avr. 2017Abbott Diabetes Care Inc.Closed loop control with improved alarm functions
US961578014 avr. 200811 avr. 2017Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in medical communication system
US962269130 oct. 201218 avr. 2017Abbott Diabetes Care Inc.Model based variable risk false glucose threshold alarm prevention mechanism
US962541319 mai 201518 avr. 2017Abbott Diabetes Care Inc.Analyte monitoring devices and methods therefor
US962957826 mars 201625 avr. 2017Abbott Diabetes Care Inc.Method and system for dynamically updating calibration parameters for an analyte sensor
US963606824 juin 20162 mai 2017Abbott Diabetes Care Inc.Analyte sensor and apparatus for insertion of the sensor
US963645015 févr. 20082 mai 2017Udo HossPump system modular components for delivering medication and analyte sensing at seperate insertion sites
US964905711 mai 201516 mai 2017Abbott Diabetes Care Inc.Analyte monitoring system and methods
US966205622 mai 201430 mai 2017Abbott Diabetes Care Inc.Optimizing analyte sensor calibration
US966916216 mars 20166 juin 2017Abbott Diabetes Care Inc.Method and system for providing basal profile modification in analyte monitoring and management systems
US967529029 oct. 201313 juin 2017Abbott Diabetes Care Inc.Sensitivity calibration of in vivo sensors used to measure analyte concentration
US968718330 mars 201227 juin 2017Abbott Diabetes Care Inc.Medical device inserters and processes of inserting and using medical devices
US969368816 juil. 20154 juil. 2017Abbott Diabetes Care Inc.Method and system for providing data communication in continuous glucose monitoring and management system
US969371327 juin 20164 juil. 2017Abbott Diabetes Care Inc.Analyte sensor devices, connections, and methods
US96941443 déc. 20134 juil. 2017Sanofi-Aventis Deutschland GmbhSampling module device and method
US97240218 déc. 20148 août 2017Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US973058410 févr. 201415 août 2017Abbott Diabetes Care Inc.Glucose measuring device for use in personal area network
US97306235 févr. 201615 août 2017Abbott Diabetes Care Inc.Analyte sensor calibration management
US973065015 janv. 201615 août 2017Abbott Diabetes Care Inc.Alarm characterization for analyte monitoring devices and systems
US973724917 juin 201522 août 2017Abbott Diabetes Care Inc.Method and apparatus for providing data processing and control in a medical communication system
US974386229 mars 201229 août 2017Abbott Diabetes Care Inc.Systems and methods for transcutaneously implanting medical devices
US97438631 juin 201629 août 2017Abbott Diabetes Care Inc.Method and system for powering an electronic device
US974386525 juin 201629 août 2017Abbott Diabetes Care Inc.Assessing measures of glycemic variability
US974386613 juil. 201629 août 2017Abbott Diabetes Care Inc.Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US97438724 févr. 201629 août 2017Abbott Diabetes Care Inc.Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US97504398 avr. 20165 sept. 2017Abbott Diabetes Care Inc.Method and apparatus for providing notification function in analyte monitoring systems
US975044012 avr. 20165 sept. 2017Abbott Diabetes Care Inc.Method and system for providing data management in data monitoring system
US975044427 avr. 20165 sept. 2017Abbott Diabetes Care Inc.Interconnect for on-body analyte monitoring device
US20060003398 *15 juil. 20055 janv. 2006Therasense, Inc.Subcutaneous glucose electrode
US20080081977 *2 oct. 20063 avr. 2008Abbott Diabetes Care, Inc.Method and System for Dynamically Updating Calibration Parameters for an Analyte Sensor
US20100268050 *28 juin 201021 oct. 2010Abbott Diabetes Care Inc.Analyte Monitoring Device and Methods of Use
CN102483397A *6 juil. 201030 mai 2012威立雅水务技术支持公司Device for measuring at least one property of water
WO2011003923A1 *6 juil. 201013 janv. 2011Veolia Water Solutions & Technologies SupportDevice for measuring at least one property of water
Classifications
Classification aux États-Unis435/14
Classification internationaleA61B5/145, G01N27/327, A61B5/1486, A61B5/1495, C12M1/40, A61B5/1473, C12Q1/54, C12Q1/00
Classification coopérativeY10S435/962, Y10S435/917, Y10S435/817, C12Q1/006, C12Q1/54
Classification européenneC12Q1/54, C12Q1/00B6B